{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T06:47:28Z","timestamp":1794293248718,"version":"4.9.0"},"reference-count":216,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T00:00:00Z","timestamp":1775606400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82130109"],"award-info":[{"award-number":["82130109"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U2202214"],"award-info":[{"award-number":["U2202214"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["U21A20410"],"award-info":[{"award-number":["U21A20410"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100019026","name":"Guangxi Key Laboratory of Metabolic Disease Research","doi-asserted-by":"publisher","award":["2202401"],"award-info":[{"award-number":["2202401"]}],"id":[{"id":"10.13039\/100019026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100019018","name":"Chinese Academy of Medical Sciences Initiative for Innovative Medicine","doi-asserted-by":"publisher","award":["2021-I2M-1-020"],"award-info":[{"award-number":["2021-I2M-1-020"]}],"id":[{"id":"10.13039\/501100019018","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Parkinson's disease (PD) is a neurodegenerative disorder primarily characterized by motor impairments such as bradykinesia, tremor, and rigidity. Its neuropathological hallmarks include the progressive loss of dopaminergic neurons in the substantia nigra pars compacta (SNc) and the aggregation of \u03b1-synuclein (\u03b1-syn) into Lewy bodies (LBs), which gradually spread to other central nervous system regions and peripheral tissues. The etiology of PD is multifactorial, involving a complex interplay of genetic predisposition, aging, environmental exposures, and lifestyle factors. Disease pathogenesis is predominantly driven by the synergistic action of core pathological mechanisms, including \u03b1-syn aggregation, oxidative stress (OS), mitochondrial dysfunction, and neuroinflammation. In recent years, the role of peripheral-central communication pathways in disease initiation and propagation has garnered significant attention. To date, pharmacotherapy remains the mainstay for improving the quality of life in PD patients. The most commonly used clinical agents primarily target the replenishment of depleted dopamine in the brain. However, these medications only alleviate symptoms and do not slow disease progression. This inherent limitation underscores the urgent need for more effective therapeutic strategies. This review aims to systematically outline the network of PD pathogenesis and the evolution of its treatment strategies, with a particular emphasis on a holistic perspective from etiology to therapy. It critically evaluates current bottlenecks in drug treatment and provides an in-depth analysis of potential candidate drugs for PD, as well as the latest advances in \u03b1-syn-targeted immunotherapies, iPSC-based regenerative therapies, and gene therapies. Building on this foundation, we further argue that the future of PD management must shift towards integrated, multi-target, and personalized therapeutic strategies to overcome existing efficacy barriers.<\/jats:p>","DOI":"10.1186\/s43556-026-00445-0","type":"journal-article","created":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:36:13Z","timestamp":1775637373000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Parkinson's disease: pathogenesis and therapeutic strategies"],"prefix":"10.1186","volume":"7","author":[{"given":"Shanshan","family":"Zhang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingyu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ye","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qianchen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shifeng","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hefei","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naihong","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,8]]},"reference":[{"key":"445_CR1","doi-asserted-by":"publisher","first-page":"2940","DOI":"10.1002\/mds.28762","volume":"36","author":"S Qi","year":"2021","unstructured":"Qi S, Yin P, Wang L, Qu M, Kan GL, Zhang H, et al. Prevalence of parkinson\u2019s disease: a community-based study in China. Mov Disord Off J Mov Disord Soc. 2021;36:2940\u20134. https:\/\/doi.org\/10.1002\/mds.28762.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"445_CR2","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/S1474-4422(18)30295-3","volume":"17","author":"GBD 2016 Parkinson\u2019s Disease Collaborators","year":"2018","unstructured":"GBD 2016 Parkinson\u2019s Disease Collaborators. Global, regional, and national burden of Parkinson\u2019s disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018;17:939\u201353. https:\/\/doi.org\/10.1016\/S1474-4422(18)30295-3.","journal-title":"Lancet Neurol"},{"key":"445_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1016\/S0140-6736(23)01478-2","volume":"403","author":"HR Morris","year":"2024","unstructured":"Morris HR, Spillantini MG, Sue CM, Williams-Gray CH. The pathogenesis of parkinson\u2019s disease. Lancet Lond Engl. 2024;403:293\u2013304. https:\/\/doi.org\/10.1016\/S0140-6736(23)01478-2.","journal-title":"Lancet Lond Engl"},{"key":"445_CR4","doi-asserted-by":"publisher","unstructured":"Global burden of 292 causes of death in 204 countries and territories and 660 subnational locations, 1990\u20132023: a systematic analysis for the Global Burden of Disease Study 2023. Lancet Lond Engl. 2025;406. https:\/\/doi.org\/10.1016\/S0140-6736(25)01917-8.","DOI":"10.1016\/S0140-6736(25)01917-8"},{"key":"445_CR5","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.2174\/1570159X15666170510143821","volume":"16","author":"N Tambasco","year":"2018","unstructured":"Tambasco N, Romoli M, Calabresi P. Levodopa in parkinson\u2019s disease: current status and future developments. Curr Neuropharmacol. 2018;16:1239\u201352. https:\/\/doi.org\/10.2174\/1570159X15666170510143821.","journal-title":"Curr Neuropharmacol"},{"key":"445_CR6","doi-asserted-by":"publisher","first-page":"102902","DOI":"10.1016\/j.arr.2025.102902","volume":"112","author":"X Li","year":"2025","unstructured":"Li X, Luo X, Cao X, Thomas ER, Wang W, Zhou X, et al. Sirtuins in parkinson\u2019s disease: molecular mechanisms and pathophysiological roles. Ageing Res Rev. 2025;112:102902. https:\/\/doi.org\/10.1016\/j.arr.2025.102902.","journal-title":"Ageing Res Rev"},{"issue":"25","key":"445_CR7","doi-asserted-by":"publisher","first-page":"00352","DOI":"10.1016\/j.jare.2025.05.034","volume":"S2090\u20131232","author":"T Liu","year":"2025","unstructured":"Liu T, Wu H, Wei J. Beyond the brain: exploring the multi-organ axes in Parkinson\u2019s disease pathogenesis. J Adv Res. 2025;S2090\u20131232(25):00352\u201362. https:\/\/doi.org\/10.1016\/j.jare.2025.05.034.","journal-title":"J Adv Res"},{"key":"445_CR8","doi-asserted-by":"publisher","first-page":"10","DOI":"10.18773\/austprescr.003","volume":"48","author":"N Mouchaileh","year":"2025","unstructured":"Mouchaileh N, Cameron J. Device-assisted therapies for Parkinson disease. Aust Prescr. 2025;48:10\u20137. https:\/\/doi.org\/10.18773\/austprescr.003.","journal-title":"Aust Prescr"},{"key":"445_CR9","doi-asserted-by":"publisher","first-page":"1281","DOI":"10.3233\/JPD-230250","volume":"13","author":"JS Bogers","year":"2023","unstructured":"Bogers JS, Bloem BR, Den Heijer JM. The etiology of parkinson\u2019s disease: new perspectives from gene-environment interactions. J Park Dis. 2023;13:1281\u20138. https:\/\/doi.org\/10.3233\/JPD-230250.","journal-title":"J Park Dis"},{"key":"445_CR10","doi-asserted-by":"publisher","first-page":"2321","DOI":"10.3233\/JPD-223363","volume":"12","author":"C Coleman","year":"2022","unstructured":"Coleman C, Martin I. Unraveling parkinson\u2019s disease neurodegeneration: does aging hold the clues? J Park Dis. 2022;12:2321\u201338. https:\/\/doi.org\/10.3233\/JPD-223363.","journal-title":"J Park Dis"},{"key":"445_CR11","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1016\/S0140-6736(23)01419-8","volume":"403","author":"Y Ben-Shlomo","year":"2024","unstructured":"Ben-Shlomo Y, Darweesh S, Llibre-Guerra J, Marras C, San Luciano M, Tanner C. The epidemiology of parkinson\u2019s disease. Lancet Lond Engl. 2024;403:283\u201392. https:\/\/doi.org\/10.1016\/S0140-6736(23)01419-8.","journal-title":"Lancet Lond Engl"},{"key":"445_CR12","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1016\/j.cell.2016.11.018","volume":"167","author":"TR Sampson","year":"2016","unstructured":"Sampson TR, Debelius JW, Thron T, Janssen S, Shastri GG, Ilhan ZE, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of parkinson\u2019s disease. Cell. 2016;167:1469-1480.e12. https:\/\/doi.org\/10.1016\/j.cell.2016.11.018.","journal-title":"Cell"},{"key":"445_CR13","doi-asserted-by":"publisher","first-page":"a041774","DOI":"10.1101\/cshperspect.a041774","volume":"15","author":"A Westenberger","year":"2025","unstructured":"Westenberger A, Br\u00fcggemann N, Klein C. Genetics of parkinson\u2019s disease: from causes to treatment. Cold Spring Harb Perspect Med. 2025;15:a041774. https:\/\/doi.org\/10.1101\/cshperspect.a041774.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"445_CR14","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1126\/science.276.5321.2045","volume":"276","author":"MH Polymeropoulos","year":"1997","unstructured":"Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, et al. Mutation in the alpha-synuclein gene identified in families with Parkinson\u2019s disease. Science. 1997;276:2045\u20137. https:\/\/doi.org\/10.1126\/science.276.5321.2045.","journal-title":"Science"},{"key":"445_CR15","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1016\/S1474-4422(19)30287-X","volume":"19","author":"C Blauwendraat","year":"2020","unstructured":"Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson\u2019s disease. Lancet Neurol. 2020;19:170\u20138. https:\/\/doi.org\/10.1016\/S1474-4422(19)30287-X.","journal-title":"Lancet Neurol"},{"key":"445_CR16","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1097\/WCO.0000000000001167","volume":"36","author":"A Cherian","year":"2023","unstructured":"Cherian A, Divya KP, Vijayaraghavan A. Parkinson\u2019s disease - genetic cause. Curr Opin Neurol. 2023;36:292\u2013301. https:\/\/doi.org\/10.1097\/WCO.0000000000001167.","journal-title":"Curr Opin Neurol."},{"key":"445_CR17","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1038\/s41531-021-00196-5","volume":"7","author":"CC Pedersen","year":"2021","unstructured":"Pedersen CC, Lange J, F\u00f8rland MGG, Macleod AD, Alves G, Maple-Gr\u00f8dem J. A systematic review of associations between common SNCA variants and clinical heterogeneity in Parkinson\u2019s disease. NPJ Park Dis. 2021;7:54. https:\/\/doi.org\/10.1038\/s41531-021-00196-5.","journal-title":"NPJ Park Dis"},{"key":"445_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.neuroscience.2019.01.006","volume":"401","author":"AA Rahman","year":"2019","unstructured":"Rahman AA, Morrison BE. Contributions of VPS35 mutations to Parkinson\u2019s disease. Neuroscience. 2019;401:1\u201310. https:\/\/doi.org\/10.1016\/j.neuroscience.2019.01.006.","journal-title":"Neuroscience"},{"key":"445_CR19","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1136\/jnnp-2019-322338","volume":"91","author":"J Jankovic","year":"2020","unstructured":"Jankovic J, Tan EK. Parkinson\u2019s disease: etiopathogenesis and treatment. J Neurol Neurosurg Psychiatry. 2020;91:795\u2013808. https:\/\/doi.org\/10.1136\/jnnp-2019-322338.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"445_CR20","doi-asserted-by":"publisher","first-page":"1499","DOI":"10.1002\/mds.28517","volume":"36","author":"C Wittke","year":"2021","unstructured":"Wittke C, Petkovic S, Dobricic V, Schaake S, MDS\u2010endorsed PSP Study Group, Respondek G, et al. Genotype\u2013Phenotype Relations for the Atypical Parkinsonism Genes: MDSGene Systematic Review. Mov Disord. 2021;36:1499\u2013510. https:\/\/doi.org\/10.1002\/mds.28517.","journal-title":"Mov Disord"},{"key":"445_CR21","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/s43587-024-00760-7","volume":"5","author":"EG Chew","year":"2025","unstructured":"Chew EG, Liu Z, Li Z, Chung SJ, Lian MM, Tandiono M, et al. Exome sequencing in Asian populations identifies low-frequency and rare coding variation influencing Parkinson\u2019s disease risk. Nat Aging. 2025;5:205\u201318. https:\/\/doi.org\/10.1038\/s43587-024-00760-7.","journal-title":"Nat Aging"},{"key":"445_CR22","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.3390\/cells11081261","volume":"11","author":"L Smith","year":"2022","unstructured":"Smith L, Schapira AHV. GBA variants and Parkinson disease: mechanisms and treatments. Cells. 2022;11:1261. https:\/\/doi.org\/10.3390\/cells11081261.","journal-title":"Cells"},{"key":"445_CR23","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1146\/annurev-pathmechdis-031521-034145","volume":"18","author":"H Ye","year":"2023","unstructured":"Ye H, Robak LA, Yu M, Cykowski M, Shulman JM. Genetics and pathogenesis of Parkinson\u2019s syndrome. Annu Rev Pathol. 2023;18:95\u2013121. https:\/\/doi.org\/10.1146\/annurev-pathmechdis-031521-034145.","journal-title":"Annu Rev Pathol"},{"key":"445_CR24","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(19)30320-5","volume":"18","author":"MA Nalls","year":"2019","unstructured":"Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson\u2019s disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019;18:1091\u2013102. https:\/\/doi.org\/10.1016\/S1474-4422(19)30320-5.","journal-title":"Lancet Neurol"},{"key":"445_CR25","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(25)00287-X","volume":"24","author":"ER Dorsey","year":"2025","unstructured":"Dorsey ER, De Miranda BR, Hussain S, Bloem BR, Elbaz A, Llibre-Guerra J, et al. Environmental toxicants and Parkinson\u2019s disease: recent evidence, risks, and prevention opportunities. Lancet Neurol. 2025;24:976\u201386. https:\/\/doi.org\/10.1016\/S1474-4422(25)00287-X.","journal-title":"Lancet Neurol"},{"key":"445_CR26","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41392-024-02071-0","volume":"10","author":"L Chen","year":"2025","unstructured":"Chen L, Shen Q, Liu Y, Zhang Y, Sun L, Ma X, et al. Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases. Signal Transduct Target Ther. 2025;10:31. https:\/\/doi.org\/10.1038\/s41392-024-02071-0.","journal-title":"Signal Transduct Target Ther"},{"key":"445_CR27","doi-asserted-by":"publisher","first-page":"2803","DOI":"10.1038\/s41467-023-38215-z","volume":"14","author":"KC Paul","year":"2023","unstructured":"Paul KC, Krolewski RC, Lucumi Moreno E, Blank J, Holton KM, Ahfeldt T, et al. A pesticide and iPSC dopaminergic neuron screen identifies and classifies Parkinson-relevant pesticides. Nat Commun. 2023;14:2803. https:\/\/doi.org\/10.1038\/s41467-023-38215-z.","journal-title":"Nat Commun"},{"key":"445_CR28","doi-asserted-by":"publisher","unstructured":"Gao Y, Tang X, Yao J, Sun T, Chen Y, Cheng C, et al. Targeting the bile acid receptor TGR5 with Gentiopicroside to activate Nrf2 antioxidant signaling and mitigate Parkinson\u2019s disease in an MPTP mouse model. J Adv Res. 2025;:S2090\u20131232(25)00356-X. https:\/\/doi.org\/10.1016\/j.jare.2025.05.039.","DOI":"10.1016\/j.jare.2025.05.039"},{"key":"445_CR29","doi-asserted-by":"publisher","first-page":"138569","DOI":"10.1016\/j.jhazmat.2025.138569","volume":"494","author":"F Liang","year":"2025","unstructured":"Liang F, Xu Z, Ding L, Zhu Z, Chen M, Shu H, et al. Biomass fuel induces neuroinflammation and neurodegeneration via the astrocyte-microglia IL-17A\/IL-17RA pathway. J Hazard Mater. 2025;494:138569. https:\/\/doi.org\/10.1016\/j.jhazmat.2025.138569.","journal-title":"J Hazard Mater"},{"key":"445_CR30","doi-asserted-by":"publisher","first-page":"894","DOI":"10.1002\/mds.28922","volume":"37","author":"H Murata","year":"2022","unstructured":"Murata H, Barnhill LM, Bronstein JM. Air pollution and the risk of Parkinson\u2019s disease: a review. Mov Disord Off J Mov Disord Soc. 2022;37:894\u2013904. https:\/\/doi.org\/10.1002\/mds.28922.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"445_CR31","doi-asserted-by":"publisher","first-page":"10808","DOI":"10.3390\/ijms231810808","volume":"23","author":"M Huang","year":"2022","unstructured":"Huang M, Bargues-Carot A, Riaz Z, Wickham H, Zenitsky G, Jin H, et al. Impact of environmental risk factors on mitochondrial dysfunction, neuroinflammation, protein misfolding, and oxidative stress in the etiopathogenesis of Parkinson\u2019s disease. Int J Mol Sci. 2022;23:10808. https:\/\/doi.org\/10.3390\/ijms231810808.","journal-title":"Int J Mol Sci"},{"key":"445_CR32","doi-asserted-by":"publisher","first-page":"267","DOI":"10.3233\/JPD-212851","volume":"12","author":"C Domenighetti","year":"2022","unstructured":"Domenighetti C, Sugier P-E, Sreelatha AAK, Schulte C, Grover S, Mohamed O, et al. Mendelian randomisation study of smoking, alcohol, and coffee drinking in relation to Parkinson\u2019s disease. J Park Dis. 2022;12:267\u201382. https:\/\/doi.org\/10.3233\/JPD-212851.","journal-title":"J Park Dis"},{"key":"445_CR33","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s43556-025-00307-1","volume":"6","author":"C Chen","year":"2025","unstructured":"Chen C, Wang G-Q, Li D, Zhang F. Microbiota-gut-brain axis in neurodegenerative diseases: molecular mechanisms and therapeutic targets. Mol Biomed. 2025;6:64. https:\/\/doi.org\/10.1186\/s43556-025-00307-1.","journal-title":"Mol Biomed"},{"key":"445_CR34","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.1007\/s00415-019-09320-1","volume":"267","author":"M Lubomski","year":"2020","unstructured":"Lubomski M, Tan AH, Lim S-Y, Holmes AJ, Davis RL, Sue CM. Parkinson\u2019s disease and the gastrointestinal microbiome. J Neurol. 2020;267:2507\u201323. https:\/\/doi.org\/10.1007\/s00415-019-09320-1.","journal-title":"J Neurol"},{"key":"445_CR35","doi-asserted-by":"publisher","first-page":"157","DOI":"10.31083\/j.jin2206157","volume":"22","author":"W Zhang","year":"2023","unstructured":"Zhang W, Ye Y, Song J, Sang T, Xia T, Xie L, et al. Research progress of microbiota-gut-brain axis in Parkinson\u2019s disease. J Integr Neurosci. 2023;22:157. https:\/\/doi.org\/10.31083\/j.jin2206157.","journal-title":"J Integr Neurosci"},{"key":"445_CR36","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.alit.2025.01.004","volume":"74","author":"N Fukasawa","year":"2025","unstructured":"Fukasawa N, Tsunoda J, Sunaga S, Kiyohara H, Nakamoto N, Teratani T, et al. The gut-organ axis: clinical aspects and immune mechanisms. Allergol Int Off J Jpn Soc Allergol. 2025;74:197\u2013209. https:\/\/doi.org\/10.1016\/j.alit.2025.01.004.","journal-title":"Allergol Int Off J Jpn Soc Allergol"},{"key":"445_CR37","doi-asserted-by":"publisher","first-page":"101812","DOI":"10.1016\/j.arr.2022.101812","volume":"84","author":"JC Claudino Dos Santos","year":"2023","unstructured":"Claudino Dos Santos JC, Lima MPP, Brito GAdeC, Viana GSdeB. Role of enteric glia and microbiota-gut-brain axis in parkinson disease pathogenesis. Ageing Res Rev. 2023;84:101812. https:\/\/doi.org\/10.1016\/j.arr.2022.101812.","journal-title":"Ageing Res Rev"},{"key":"445_CR38","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/s41593-020-0589-7","volume":"23","author":"C Challis","year":"2020","unstructured":"Challis C, Hori A, Sampson TR, Yoo BB, Challis RC, Hamilton AM, et al. Gut-seeded \u03b1-synuclein fibrils promote gut dysfunction and brain pathology specifically in aged mice. Nat Neurosci. 2020;23:327\u201336. https:\/\/doi.org\/10.1038\/s41593-020-0589-7.","journal-title":"Nat Neurosci"},{"key":"445_CR39","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.bbi.2024.11.023","volume":"124","author":"L Ma","year":"2025","unstructured":"Ma L, Wang H-B, Hashimoto K. The vagus nerve: an old but new player in brain-body communication. Brain Behav Immun. 2025;124:28\u201339. https:\/\/doi.org\/10.1016\/j.bbi.2024.11.023.","journal-title":"Brain Behav Immun"},{"key":"445_CR40","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1016\/j.jare.2025.03.001","volume":"78","author":"J Li","year":"2025","unstructured":"Li J, Liu T, Xian M, Zhou K, Wei J. The power of exercise: unlocking the biological mysteries of peripheral-central crosstalk in Parkinson\u2019s disease. J Adv Res. 2025;78:717\u201332. https:\/\/doi.org\/10.1016\/j.jare.2025.03.001.","journal-title":"J Adv Res"},{"key":"445_CR41","doi-asserted-by":"publisher","first-page":"107480","DOI":"10.1016\/j.pharmthera.2020.107480","volume":"208","author":"SW-F Mok","year":"2020","unstructured":"Mok SW-F, Wong VK-W, Lo H-H, de Seabra Rodrigues Dias IR, Leung EL-H, Law BY-K, et al. Natural products-based polypharmacological modulation of the peripheral immune system for the treatment of neuropsychiatric disorders. Pharmacol Ther. 2020;208:107480. https:\/\/doi.org\/10.1016\/j.pharmthera.2020.107480.","journal-title":"Pharmacol Ther"},{"key":"445_CR42","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1186\/s40478-021-01136-3","volume":"9","author":"JF Reyes","year":"2021","unstructured":"Reyes JF, Ekmark-L\u00e9wen S, Perdiki M, Klingstedt T, Hoffmann A, Wiechec E, et al. Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson\u2019s disease. Acta Neuropathol Commun. 2021;9:46. https:\/\/doi.org\/10.1186\/s40478-021-01136-3.","journal-title":"Acta Neuropathol Commun"},{"key":"445_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/brain\/awaf313","author":"V Donadio","year":"2025","unstructured":"Donadio V, Incensi A, Rizzo G, Furia A, Bonvenga S, Olivola E, et al. Skin intraneural phosphorylated \u03b1-synuclein is a highly specific biomarker for early Parkinson\u2019s disease. Brain. 2025. https:\/\/doi.org\/10.1093\/brain\/awaf313.","journal-title":"Brain"},{"key":"445_CR44","doi-asserted-by":"publisher","first-page":"569446","DOI":"10.3389\/fneur.2020.569446","volume":"11","author":"X Liu","year":"2020","unstructured":"Liu X, Yang J, Yuan Y, He Q, Gao Y, Jiang C, et al. Optimization of the detection method for phosphorylated \u03b1-synuclein in Parkinson disease by skin biopsy. Front Neurol. 2020;11:569446. https:\/\/doi.org\/10.3389\/fneur.2020.569446.","journal-title":"Front Neurol"},{"key":"445_CR45","doi-asserted-by":"publisher","first-page":"3527","DOI":"10.1007\/s00204-025-04088-y","volume":"99","author":"O Verma","year":"2025","unstructured":"Verma O, Faizan M, Goswami S, Singh MP. An update on the involvement of inflammatory mediators in Parkinson\u2019s disease pathogenesis. Arch Toxicol. 2025;99:3527\u201352. https:\/\/doi.org\/10.1007\/s00204-025-04088-y.","journal-title":"Arch Toxicol"},{"key":"445_CR46","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1002\/ana.27202","volume":"97","author":"EA Backman","year":"2025","unstructured":"Backman EA, Gardberg M, Luntamo L, Peurla M, Vahlberg T, Borghammer P, et al. Nigral neuroinflammation and dopaminergic neurons in Parkinson\u2019s disease and atypical Parkinsonisms. Ann Neurol. 2025;97:1096\u2013109. https:\/\/doi.org\/10.1002\/ana.27202.","journal-title":"Ann Neurol"},{"key":"445_CR47","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.tins.2024.01.002","volume":"47","author":"J Wang","year":"2024","unstructured":"Wang J, Dai L, Chen S, Zhang Z, Fang X, Zhang Z. Protein-protein interactions regulating \u03b1-synuclein pathology. Trends Neurosci. 2024;47:209\u201326. https:\/\/doi.org\/10.1016\/j.tins.2024.01.002.","journal-title":"Trends Neurosci"},{"key":"445_CR48","doi-asserted-by":"publisher","first-page":"2691","DOI":"10.1007\/s12035-023-03211-3","volume":"60","author":"K Moore","year":"2023","unstructured":"Moore K, Sengupta U, Puangmalai N, Bhatt N, Kayed R. Polymorphic alpha-synuclein oligomers: characterization and differential detection with novel corresponding antibodies. Mol Neurobiol. 2023;60:2691\u2013705. https:\/\/doi.org\/10.1007\/s12035-023-03211-3.","journal-title":"Mol Neurobiol"},{"key":"445_CR49","doi-asserted-by":"publisher","first-page":"1006","DOI":"10.3390\/genes12071006","volume":"12","author":"JO Day","year":"2021","unstructured":"Day JO, Mullin S. The genetics of Parkinson\u2019s disease and implications for clinical practice. Genes. 2021;12:1006. https:\/\/doi.org\/10.3390\/genes12071006.","journal-title":"Genes"},{"key":"445_CR50","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1146\/annurev-neuro-100720-034518","volume":"44","author":"GE V\u00e1zquez-V\u00e9lez","year":"2021","unstructured":"V\u00e1zquez-V\u00e9lez GE, Zoghbi HY. Parkinson\u2019s disease genetics and pathophysiology. Annu Rev Neurosci. 2021;44:87\u2013108. https:\/\/doi.org\/10.1146\/annurev-neuro-100720-034518.","journal-title":"Annu Rev Neurosci"},{"key":"445_CR51","doi-asserted-by":"publisher","first-page":"8645","DOI":"10.3390\/ijms21228645","volume":"21","author":"X-Y Du","year":"2020","unstructured":"Du X-Y, Xie X-X, Liu R-T. The role of \u03b1-Synuclein oligomers in Parkinson\u2019s disease. Int J Mol Sci. 2020;21:8645. https:\/\/doi.org\/10.3390\/ijms21228645.","journal-title":"Int J Mol Sci"},{"key":"445_CR52","doi-asserted-by":"publisher","first-page":"23","DOI":"10.3892\/etm.2023.12311","volume":"27","author":"N Zhang","year":"2024","unstructured":"Zhang N, Yan Z, Xin H, Shao S, Xue S, Cespuglio R, et al. Relationship among \u03b1-synuclein, aging and inflammation in Parkinson\u2019s disease (Review). Exp Ther Med. 2024;27:23. https:\/\/doi.org\/10.3892\/etm.2023.12311.","journal-title":"Exp Ther Med"},{"key":"445_CR53","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1007\/s00011-022-01676-x","volume":"72","author":"Q-K Lv","year":"2023","unstructured":"Lv Q-K, Tao K-X, Wang X-B, Yao X-Y, Pang M-Z, Liu J-Y, et al. Role of \u03b1-synuclein in microglia: autophagy and phagocytosis balance neuroinflammation in Parkinson\u2019s disease. Inflamm Res. 2023;72:443\u201362. https:\/\/doi.org\/10.1007\/s00011-022-01676-x.","journal-title":"Inflamm Res"},{"key":"445_CR54","doi-asserted-by":"publisher","first-page":"1583","DOI":"10.3390\/molecules24081583","volume":"24","author":"A Singh","year":"2019","unstructured":"Singh A, Kukreti R, Saso L, Kukreti S. Oxidative stress: a key modulator in neurodegenerative diseases. Mol. 2019;24:1583. https:\/\/doi.org\/10.3390\/molecules24081583.","journal-title":"Mol"},{"key":"445_CR55","doi-asserted-by":"publisher","first-page":"103787","DOI":"10.1016\/j.redox.2025.103787","volume":"85","author":"T Liu","year":"2025","unstructured":"Liu T, Kong X, Qiao J, Wei J. Decoding Parkinson\u2019s disease: the interplay of cell death pathways, oxidative stress, and therapeutic innovations. Redox Biol. 2025;85:103787. https:\/\/doi.org\/10.1016\/j.redox.2025.103787.","journal-title":"Redox Biol"},{"key":"445_CR56","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41392-023-01353-3","volume":"8","author":"X Dong-Chen","year":"2023","unstructured":"Dong-Chen X, Yong C, Yang X, Chen-Yu S, Li-Hua P. Signaling pathways in Parkinson\u2019s disease: molecular mechanisms and therapeutic interventions. Signal Transduct Target Ther. 2023;8:73. https:\/\/doi.org\/10.1038\/s41392-023-01353-3.","journal-title":"Signal Transduct Target Ther"},{"key":"445_CR57","doi-asserted-by":"publisher","first-page":"101263","DOI":"10.1016\/j.arr.2021.101263","volume":"67","author":"PA Dion\u00edsio","year":"2021","unstructured":"Dion\u00edsio PA, Amaral JD, Rodrigues CMP. Oxidative stress and regulated cell death in Parkinson\u2019s disease. Ageing Res Rev. 2021;67:101263. https:\/\/doi.org\/10.1016\/j.arr.2021.101263.","journal-title":"Ageing Res Rev"},{"key":"445_CR58","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.3390\/ijms24033022","volume":"24","author":"J Tchekalarova","year":"2023","unstructured":"Tchekalarova J, Tzoneva R. Oxidative stress and aging as risk factors for Alzheimer\u2019s Disease and Parkinson\u2019s disease: the role of the antioxidant melatonin. Int J Mol Sci. 2023;24:3022. https:\/\/doi.org\/10.3390\/ijms24033022.","journal-title":"Int J Mol Sci"},{"key":"445_CR59","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1186\/s13024-024-00774-0","volume":"19","author":"Z Riaz","year":"2024","unstructured":"Riaz Z, Richardson GS, Jin H, Zenitsky G, Anantharam V, Kanthasamy A, et al. Nuclear pore and nucleocytoplasmic transport impairment in oxidative stress-induced neurodegeneration: relevance to molecular mechanisms in Pathogenesis of Parkinson\u2019s and other related neurodegenerative diseases. Mol Neurodegener. 2024;19:87. https:\/\/doi.org\/10.1186\/s13024-024-00774-0.","journal-title":"Mol Neurodegener"},{"key":"445_CR60","doi-asserted-by":"publisher","first-page":"e13012","DOI":"10.1111\/bpa.13012","volume":"32","author":"Z Chen","year":"2022","unstructured":"Chen Z, Rasheed M, Deng Y. The epigenetic mechanisms involved in mitochondrial dysfunction: implication for Parkinson\u2019s disease. Brain Pathol. 2022;32:e13012. https:\/\/doi.org\/10.1111\/bpa.13012.","journal-title":"Brain Pathol"},{"key":"445_CR61","doi-asserted-by":"publisher","first-page":"102856","DOI":"10.1016\/j.arr.2025.102856","volume":"112","author":"J Liang","year":"2025","unstructured":"Liang J, Su Z, Su G, Rasheed M, Tang S, Sunniya H, et al. Strategies to rescue mitochondria in Parkinson\u2019s disease: the significance of mitochondrial transfer. Ageing Res Rev. 2025;112:102856. https:\/\/doi.org\/10.1016\/j.arr.2025.102856.","journal-title":"Ageing Res Rev"},{"key":"445_CR62","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/s13024-023-00676-7","volume":"18","author":"MT Henrich","year":"2023","unstructured":"Henrich MT, Oertel WH, Surmeier DJ, Geibl FF. Mitochondrial dysfunction in Parkinson\u2019s disease - a key disease hallmark with therapeutic potential. Mol Neurodegener. 2023;18:83. https:\/\/doi.org\/10.1186\/s13024-023-00676-7.","journal-title":"Mol Neurodegener"},{"key":"445_CR63","doi-asserted-by":"publisher","first-page":"101931","DOI":"10.1016\/j.arr.2023.101931","volume":"87","author":"Y-Y Zhang","year":"2023","unstructured":"Zhang Y-Y, Li X-S, Ren K-D, Peng J, Luo X-J. Restoration of metal homeostasis: a potential strategy against neurodegenerative diseases. Ageing Res Rev. 2023;87:101931. https:\/\/doi.org\/10.1016\/j.arr.2023.101931.","journal-title":"Ageing Res Rev"},{"key":"445_CR64","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.toxrep.2021.03.009","volume":"8","author":"I Ullah","year":"2021","unstructured":"Ullah I, Zhao L, Hai Y, Fahim M, Alwayli D, Wang X, et al. Metal elements and pesticides as risk factors for Parkinson\u2019s disease - A review. Toxicol Rep. 2021;8:607\u201316. https:\/\/doi.org\/10.1016\/j.toxrep.2021.03.009.","journal-title":"Toxicol Rep"},{"key":"445_CR65","doi-asserted-by":"publisher","first-page":"2140","DOI":"10.3390\/nu15092140","volume":"15","author":"B Wang","year":"2023","unstructured":"Wang B, Fang T, Chen H. Zinc and central nervous system disorders. Nutrients. 2023;15:2140. https:\/\/doi.org\/10.3390\/nu15092140.","journal-title":"Nutrients"},{"key":"445_CR66","doi-asserted-by":"publisher","first-page":"2695","DOI":"10.14336\/AD.2025.0440","volume":"16","author":"SK Soman","year":"2025","unstructured":"Soman SK, Woodruff MRJ, Dagda RK. The Mitochondrial foundations of Parkinson\u2019s disease: therapeutic implications. Aging Dis. 2025;16:2695\u2013720. https:\/\/doi.org\/10.14336\/AD.2025.0440.","journal-title":"Aging Dis"},{"key":"445_CR67","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1186\/s40035-020-00221-2","volume":"9","author":"HS Kwon","year":"2020","unstructured":"Kwon HS, Koh S-H. Neuroinflammation in neurodegenerative disorders: the roles of microglia and astrocytes. Transl Neurodegener. 2020;9:42. https:\/\/doi.org\/10.1186\/s40035-020-00221-2.","journal-title":"Transl Neurodegener"},{"key":"445_CR68","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1038\/s41392-023-01588-0","volume":"8","author":"C Gao","year":"2023","unstructured":"Gao C, Jiang J, Tan Y, Chen S. Microglia in neurodegenerative diseases: mechanism and potential therapeutic targets. Signal Transduct Target Ther. 2023;8:359. https:\/\/doi.org\/10.1038\/s41392-023-01588-0.","journal-title":"Signal Transduct Target Ther"},{"key":"445_CR69","doi-asserted-by":"publisher","first-page":"6237","DOI":"10.1038\/s41467-021-26519-x","volume":"12","author":"S Bido","year":"2021","unstructured":"Bido S, Muggeo S, Massimino L, Marzi MJ, Giannelli SG, Melacini E, et al. Microglia-specific overexpression of \u03b1-synuclein leads to severe dopaminergic neurodegeneration by phagocytic exhaustion and oxidative toxicity. Nat Commun. 2021;12:6237. https:\/\/doi.org\/10.1038\/s41467-021-26519-x.","journal-title":"Nat Commun"},{"key":"445_CR70","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41423-025-01275-w","volume":"22","author":"W Xu","year":"2025","unstructured":"Xu W, Huang Y, Zhou R. NLRP3 inflammasome in neuroinflammation and central nervous system diseases. Cell Mol Immunol. 2025;22:341\u201355. https:\/\/doi.org\/10.1038\/s41423-025-01275-w.","journal-title":"Cell Mol Immunol"},{"key":"445_CR71","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1002\/glia.23908","volume":"69","author":"BP Heithoff","year":"2021","unstructured":"Heithoff BP, George KK, Phares AN, Zuidhoek IA, Munoz-Ballester C, Robel S. Astrocytes are necessary for blood-brain barrier maintenance in the adult mouse brain. Glia. 2021;69:436\u201372. https:\/\/doi.org\/10.1002\/glia.23908.","journal-title":"Glia"},{"key":"445_CR72","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s40035-024-00459-0","volume":"13","author":"Q Wang","year":"2024","unstructured":"Wang Q, Yang S, Zhang X, Zhang S, Chen L, Wang W, et al. Inflammasomes in neurodegenerative diseases. Transl Neurodegener. 2024;13:65. https:\/\/doi.org\/10.1186\/s40035-024-00459-0.","journal-title":"Transl Neurodegener"},{"key":"445_CR73","doi-asserted-by":"publisher","first-page":"e14411","DOI":"10.1111\/cns.14411","volume":"30","author":"H Li","year":"2024","unstructured":"Li H, Zeng F, Huang C, Pu Q, Thomas ER, Chen Y, et al. The potential role of glucose metabolism, lipid metabolism, and amino acid metabolism in the treatment of Parkinson\u2019s disease. CNS Neurosci Ther. 2024;30:e14411. https:\/\/doi.org\/10.1111\/cns.14411.","journal-title":"CNS Neurosci Ther"},{"key":"445_CR74","doi-asserted-by":"publisher","first-page":"1585","DOI":"10.3233\/JPD-212725","volume":"11","author":"K Komici","year":"2021","unstructured":"Komici K, Femminella GD, Bencivenga L, Rengo G, Pagano G. Diabetes mellitus and Parkinson\u2019s disease: a systematic review and meta-analyses. J Park Dis. 2021;11:1585\u201396. https:\/\/doi.org\/10.3233\/JPD-212725.","journal-title":"J Park Dis"},{"key":"445_CR75","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1016\/j.neurobiolaging.2018.05.010","volume":"69","author":"J Renaud","year":"2018","unstructured":"Renaud J, Bassareo V, Beaulieu J, Pinna A, Schlich M, Lavoie C, et al. Dopaminergic neurodegeneration in a rat model of long-term hyperglycemia: preferential degeneration of the nigrostriatal motor pathway. Neurobiol Aging. 2018;69:117\u201328. https:\/\/doi.org\/10.1016\/j.neurobiolaging.2018.05.010.","journal-title":"Neurobiol Aging"},{"key":"445_CR76","doi-asserted-by":"publisher","first-page":"1636","DOI":"10.1002\/mds.28124","volume":"35","author":"I P\u00e9rez-Taboada","year":"2020","unstructured":"P\u00e9rez-Taboada I, Alberquilla S, Mart\u00edn ED, Anand R, Vietti-Michelina S, Tebeka NN, et al. Diabetes causes dysfunctional dopamine neurotransmission favoring nigrostriatal degeneration in mice. Mov Disord. 2020;35:1636\u201348. https:\/\/doi.org\/10.1002\/mds.28124.","journal-title":"Mov Disord"},{"key":"445_CR77","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s40035-022-00288-z","volume":"11","author":"Y-Q Lv","year":"2022","unstructured":"Lv Y-Q, Yuan L, Sun Y, Dou H-W, Su J-H, Hou Z-P, et al. Long-term hyperglycemia aggravates \u03b1-synuclein aggregation and dopaminergic neuronal loss in a Parkinson\u2019s disease mouse model. Transl Neurodegener. 2022;11:14. https:\/\/doi.org\/10.1186\/s40035-022-00288-z.","journal-title":"Transl Neurodegener"},{"key":"445_CR78","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s12264-019-00459-5","volume":"36","author":"C-J Su","year":"2020","unstructured":"Su C-J, Shen Z, Cui R-X, Huang Y, Xu D-L, Zhao F-L, et al. Thioredoxin-interacting protein (TXNIP) regulates Parkin\/PINK1-mediated mitophagy in dopaminergic neurons under high-glucose conditions: implications for molecular links between Parkinson\u2019s disease and diabetes. Neurosci Bull. 2020;36:346\u201358. https:\/\/doi.org\/10.1007\/s12264-019-00459-5.","journal-title":"Neurosci Bull"},{"key":"445_CR79","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41575-019-0250-7","volume":"17","author":"C-W Ko","year":"2020","unstructured":"Ko C-W, Qu J, Black DD, Tso P. Regulation of intestinal lipid metabolism: current concepts and relevance to disease. Nat Rev Gastroenterol Hepatol. 2020;17:169\u201383. https:\/\/doi.org\/10.1038\/s41575-019-0250-7.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"445_CR80","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1016\/j.semcdb.2020.08.012","volume":"112","author":"TJ Tracey","year":"2021","unstructured":"Tracey TJ, Kirk SE, Steyn FJ, Ngo ST. The role of lipids in the central nervous system and their pathological implications in amyotrophic lateral sclerosis. Semin Cell Dev Biol. 2021;112:69\u201381. https:\/\/doi.org\/10.1016\/j.semcdb.2020.08.012.","journal-title":"Semin Cell Dev Biol"},{"key":"445_CR81","doi-asserted-by":"publisher","first-page":"1982","DOI":"10.1038\/s41467-025-57142-9","volume":"16","author":"G Gao","year":"2025","unstructured":"Gao G, Shi Y, Deng H-X, Krainc D. Dysregulation of mitochondrial \u03b1-ketoglutarate dehydrogenase leads to elevated lipid peroxidation in CHCHD2-linked Parkinson\u2019s disease models. Nat Commun. 2025;16:1982. https:\/\/doi.org\/10.1038\/s41467-025-57142-9.","journal-title":"Nat Commun"},{"key":"445_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22147630","author":"M F","year":"2021","unstructured":"F M, D A, G M, G G, C C, I C. Parkinson\u2019s disease-related genes and lipid alteration. Int J Mol Sci. 2021. https:\/\/doi.org\/10.3390\/ijms22147630.","journal-title":"Int J Mol Sci"},{"key":"445_CR83","doi-asserted-by":"publisher","unstructured":"M T, C M, Mp A, L C, F Z. Emerging role of HDL in brain cholesterol metabolism and neurodegenerative disorders. Biochim Biophys Acta Mol Cell Biol Lipids. 2022;1867. https:\/\/doi.org\/10.1016\/j.bbalip.2022.159123.","DOI":"10.1016\/j.bbalip.2022.159123"},{"key":"445_CR84","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.jphs.2020.07.011","volume":"144","author":"L Iovino","year":"2020","unstructured":"Iovino L, Tremblay ME, Civiero L. Glutamate-induced excitotoxicity in Parkinson\u2019s disease: the role of glial cells. J Pharmacol Sci. 2020;144:151\u201364. https:\/\/doi.org\/10.1016\/j.jphs.2020.07.011.","journal-title":"J Pharmacol Sci"},{"key":"445_CR85","doi-asserted-by":"publisher","first-page":"108006","DOI":"10.1016\/j.neuropharm.2020.108006","volume":"167","author":"CA Pisan\u00f2","year":"2020","unstructured":"Pisan\u00f2 CA, Brugnoli A, Novello S, Caccia C, Keywood C, Melloni E, et al. Safinamide inhibits in vivo glutamate release in a rat model of Parkinson\u2019s disease. Neuropharmacology. 2020;167:108006. https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108006.","journal-title":"Neuropharmacology"},{"key":"445_CR86","doi-asserted-by":"publisher","first-page":"1318","DOI":"10.1021\/acs.analchem.4c05627","volume":"97","author":"H Dong","year":"2025","unstructured":"Dong H, Chen W, Xu K, Zheng L, Wei B, Liu R, et al. High selectivity fluorescence and electrochemical dual-mode detection of glutathione in the serum of Parkinson\u2019s disease model mice and humans. Anal Chem. 2025;97:1318\u201328. https:\/\/doi.org\/10.1021\/acs.analchem.4c05627.","journal-title":"Anal Chem"},{"key":"445_CR87","doi-asserted-by":"publisher","first-page":"937555","DOI":"10.3389\/fimmu.2022.937555","volume":"13","author":"M Zhu","year":"2022","unstructured":"Zhu M, Liu X, Ye Y, Yan X, Cheng Y, Zhao L, et al. Gut microbiota: a novel therapeutic target for Parkinson\u2019s disease. Front Immunol. 2022;13:937555. https:\/\/doi.org\/10.3389\/fimmu.2022.937555.","journal-title":"Front Immunol"},{"key":"445_CR88","doi-asserted-by":"publisher","first-page":"1644","DOI":"10.1002\/mds.29128","volume":"37","author":"A Xie","year":"2022","unstructured":"Xie A, Ensink E, Li P, Gordevi\u010dius J, Marshall LL, George S, et al. Bacterial butyrate in Parkinson\u2019s disease is linked to epigenetic changes and depressive symptoms. Mov Disord Off J Mov Disord Soc. 2022;37:1644\u201353. https:\/\/doi.org\/10.1002\/mds.29128.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"445_CR89","doi-asserted-by":"publisher","first-page":"3581","DOI":"10.1111\/ene.15671","volume":"30","author":"S Kleine Bardenhorst","year":"2023","unstructured":"Kleine Bardenhorst S, Cereda E, Severgnini M, Barichella M, Pezzoli G, Keshavarzian A, et al. Gut microbiota dysbiosis in Parkinson disease: a systematic review and pooled analysis. Eur J Neurol. 2023;30:3581\u201394. https:\/\/doi.org\/10.1111\/ene.15671.","journal-title":"Eur J Neurol"},{"key":"445_CR90","doi-asserted-by":"publisher","first-page":"e848","DOI":"10.1212\/WNL.0000000000013225","volume":"98","author":"S-J Chen","year":"2022","unstructured":"Chen S-J, Chen C-C, Liao H-Y, Lin Y-T, Wu Y-W, Liou J-M, et al. Association of fecal and plasma levels of short-chain fatty acids with gut microbiota and clinical severity in patients with Parkinson disease. Neurology. 2022;98:e848\u201358. https:\/\/doi.org\/10.1212\/WNL.0000000000013225.","journal-title":"Neurology"},{"key":"445_CR91","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.jare.2022.10.013","volume":"50","author":"S Salim","year":"2023","unstructured":"Salim S, Ahmad F, Banu A, Mohammad F. Gut microbiome and Parkinson\u2019s disease: perspective on pathogenesis and treatment. J Adv Res. 2023;50:83\u2013105. https:\/\/doi.org\/10.1016\/j.jare.2022.10.013.","journal-title":"J Adv Res"},{"key":"445_CR92","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s10571-021-01066-7","volume":"42","author":"N Dogra","year":"2022","unstructured":"Dogra N, Mani RJ, Katare DP. The gut-brain axis: two ways signaling in Parkinson\u2019s disease. Cell Mol Neurobiol. 2022;42:315\u201332. https:\/\/doi.org\/10.1007\/s10571-021-01066-7.","journal-title":"Cell Mol Neurobiol"},{"key":"445_CR93","doi-asserted-by":"publisher","first-page":"e53111","DOI":"10.7554\/eLife.53111","volume":"9","author":"TR Sampson","year":"2020","unstructured":"Sampson TR, Challis C, Jain N, Moiseyenko A, Ladinsky MS, Shastri GG, et al. A gut bacterial amyloid promotes \u03b1-synuclein aggregation and motor impairment in mice. Elife. 2020;9:e53111. https:\/\/doi.org\/10.7554\/eLife.53111.","journal-title":"Elife"},{"key":"445_CR94","doi-asserted-by":"publisher","first-page":"160","DOI":"10.3389\/fnagi.2018.00160","volume":"10","author":"A Yan","year":"2018","unstructured":"Yan A, Zhang Y, Lin J, Song L, Wang X, Liu Z. Partial depletion of peripheral M1 macrophages reverses motor deficits in MPTP-treated mouse by suppressing neuroinflammation and dopaminergic neurodegeneration. Front Aging Neurosci. 2018;10:160. https:\/\/doi.org\/10.3389\/fnagi.2018.00160.","journal-title":"Front Aging Neurosci"},{"key":"445_CR95","doi-asserted-by":"publisher","unstructured":"Y C, M M, R Z, C G, X D, J W, et al. Dairy-rich diet triggers hepatic \u03b1-synuclein pathology via the liver-brain axis in GBA1-related Parkinson\u2019s disease. NPJ Park Dis. 2025;11. https:\/\/doi.org\/10.1038\/s41531-025-01211-9.","DOI":"10.1038\/s41531-025-01211-9"},{"key":"445_CR96","doi-asserted-by":"publisher","first-page":"120730","DOI":"10.1016\/j.jns.2023.120730","volume":"451","author":"H Peng","year":"2023","unstructured":"Peng H, Chen S, Wu S, Shi X, Ma J, Yang H, et al. Alpha-synuclein in skin as a high-quality biomarker for Parkinson\u2019s disease. J Neurol Sci. 2023;451:120730. https:\/\/doi.org\/10.1016\/j.jns.2023.120730.","journal-title":"J Neurol Sci"},{"key":"445_CR97","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1002\/acn3.51610","volume":"9","author":"H Oizumi","year":"2022","unstructured":"Oizumi H, Yamasaki K, Suzuki H, Ohshiro S, Saito Y, Murayama S, et al. Phosphorylated alpha-synuclein in Iba1-positive macrophages in the skin of patients with Parkinson\u2019s disease. Ann Clin Transl Neurol. 2022;9:1136\u201346. https:\/\/doi.org\/10.1002\/acn3.51610.","journal-title":"Ann Clin Transl Neurol"},{"key":"445_CR98","doi-asserted-by":"publisher","first-page":"104076","DOI":"10.1016\/j.ebiom.2022.104076","volume":"80","author":"Y Han","year":"2022","unstructured":"Han Y, Wu D, Wang Y, Xie J, Zhang Z. Skin alpha-synuclein deposit patterns: a predictor of Parkinson\u2019s disease subtypes. EBioMedicine. 2022;80:104076. https:\/\/doi.org\/10.1016\/j.ebiom.2022.104076.","journal-title":"EBioMedicine"},{"key":"445_CR99","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1056\/NEJMra2401857","volume":"391","author":"CM Tanner","year":"2024","unstructured":"Tanner CM, Ostrem JL. Parkinson\u2019s disease. N Engl J Med. 2024;391:442\u201352. https:\/\/doi.org\/10.1056\/NEJMra2401857.","journal-title":"N Engl J Med"},{"key":"445_CR100","doi-asserted-by":"publisher","first-page":"1253273","DOI":"10.3389\/fimmu.2023.1253273","volume":"14","author":"F Zhang","year":"2023","unstructured":"Zhang F, Liu M, Tuo J, Zhang L, Zhang J, Yu C, et al. Levodopa-induced dyskinesia: interplay between the N-methyl-D-aspartic acid receptor and neuroinflammation. Front Immunol. 2023;14:1253273. https:\/\/doi.org\/10.3389\/fimmu.2023.1253273.","journal-title":"Front Immunol"},{"key":"445_CR101","doi-asserted-by":"publisher","first-page":"33","DOI":"10.2169\/internalmedicine.8940-21","volume":"62","author":"H Murakami","year":"2023","unstructured":"Murakami H, Shiraishi T, Umehara T, Omoto S, Iguchi Y. Recent advances in drug therapy for Parkinson\u2019s disease. Intern Med Tokyo Jpn. 2023;62:33\u201342. https:\/\/doi.org\/10.2169\/internalmedicine.8940-21.","journal-title":"Intern Med Tokyo Jpn"},{"key":"445_CR102","doi-asserted-by":"publisher","first-page":"805388","DOI":"10.3389\/fphar.2022.805388","volume":"13","author":"R Bandopadhyay","year":"2022","unstructured":"Bandopadhyay R, Mishra N, Rana R, Kaur G, Ghoneim MM, Alshehri S, et al. Molecular mechanisms and therapeutic strategies for levodopa-induced dyskinesia in Parkinson\u2019s disease: a perspective through preclinical and clinical evidence. Front Pharmacol. 2022;13:805388. https:\/\/doi.org\/10.3389\/fphar.2022.805388.","journal-title":"Front Pharmacol"},{"key":"445_CR103","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.2174\/1570159X20666220915091022","volume":"21","author":"X-Z Jing","year":"2023","unstructured":"Jing X-Z, Yang H-J, Taximaimaiti R, Wang X-P. Advances in the therapeutic use of non-ergot dopamine agonists in the treatment of motor and non-motor symptoms of Parkinson\u2019s disease. Curr Neuropharmacol. 2023;21:1224\u201340. https:\/\/doi.org\/10.2174\/1570159X20666220915091022.","journal-title":"Curr Neuropharmacol"},{"key":"445_CR104","doi-asserted-by":"publisher","first-page":"108392","DOI":"10.1016\/j.pharmthera.2023.108392","volume":"245","author":"M Ferraiolo","year":"2023","unstructured":"Ferraiolo M, Hermans E. The complex molecular pharmacology of the dopamine D2 receptor: implications for pramipexole, ropinirole, and rotigotine. Pharmacol Ther. 2023;245:108392. https:\/\/doi.org\/10.1016\/j.pharmthera.2023.108392.","journal-title":"Pharmacol Ther"},{"key":"445_CR105","doi-asserted-by":"publisher","first-page":"102691","DOI":"10.1016\/j.ajp.2021.102691","volume":"61","author":"D-Q Jiang","year":"2021","unstructured":"Jiang D-Q, Jiang L-L, Wang Y, Li M-X. The role of pramipexole in the treatment of patients with depression and Parkinson\u2019s disease: a meta-analysis of randomized controlled trials. Asian J Psychiatry. 2021;61:102691. https:\/\/doi.org\/10.1016\/j.ajp.2021.102691.","journal-title":"Asian J Psychiatry"},{"key":"445_CR106","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1007\/s40263-020-00788-4","volume":"35","author":"V Raeder","year":"2021","unstructured":"Raeder V, Boura I, Leta V, Jenner P, Reichmann H, Trenkwalder C, et al. Rotigotine transdermal patch for motor and non-motor Parkinson\u2019s Disease: a review of 12 years\u2019 clinical experience. CNS Drugs. 2021;35:215\u201331. https:\/\/doi.org\/10.1007\/s40263-020-00788-4.","journal-title":"CNS Drugs"},{"key":"445_CR107","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.3233\/JPD-230072","volume":"13","author":"F Stocchi","year":"2023","unstructured":"Stocchi F, Rascol O, Poewe W, Chaudhuri KR, Kassubek J, Lopez Manzanares L, et al. Apomorphine sublingual film compared with subcutaneous apomorphine for OFF episodes in Parkinson\u2019s Disease: an open-label, randomized, crossover study. J Park Dis. 2023;13:1329\u201342. https:\/\/doi.org\/10.3233\/JPD-230072.","journal-title":"J Park Dis"},{"key":"445_CR108","doi-asserted-by":"publisher","first-page":"762","DOI":"10.1111\/ene.15635","volume":"30","author":"X-T Chen","year":"2023","unstructured":"Chen X-T, Zhang Q, Wen S-Y, Chen F-F, Zhou C-Q. Efficacy and safety of non-ergot dopamine-receptor agonists as an adjunct to levodopa in advanced Parkinson\u2019s disease: a\u00a0network meta-analysis. Eur J Neurol. 2023;30:762\u201373. https:\/\/doi.org\/10.1111\/ene.15635.","journal-title":"Eur J Neurol"},{"key":"445_CR109","doi-asserted-by":"publisher","first-page":"16","DOI":"10.4103\/1673-5374.375299","volume":"19","author":"M Alborghetti","year":"2024","unstructured":"Alborghetti M, Bianchini E, De Carolis L, Galli S, Pontieri FE, Rinaldi D. Type-B monoamine oxidase inhibitors in neurological diseases: clinical applications based on preclinical findings. Neural Regen Res. 2024;19:16\u201321. https:\/\/doi.org\/10.4103\/1673-5374.375299.","journal-title":"Neural Regen Res"},{"key":"445_CR110","doi-asserted-by":"publisher","unstructured":"Yy T, P J, Sd C. Monoamine Oxidase-B inhibitors for the treatment of Parkinson\u2019s disease: past, present, and future. J Park Dis. 2022;12. https:\/\/doi.org\/10.3233\/JPD-212976.","DOI":"10.3233\/JPD-212976"},{"key":"445_CR111","doi-asserted-by":"publisher","first-page":"1134472","DOI":"10.3389\/fnagi.2023.1134472","volume":"15","author":"K Wang","year":"2023","unstructured":"Wang K, Liu Z-H, Li X-Y, Li Y-F, Li J-R, Hui J-J, et al. Efficacy and safety of selegiline for the treatment of Parkinson\u2019s disease: a systematic review and meta-analysis. Front Aging Neurosci. 2023;15:1134472. https:\/\/doi.org\/10.3389\/fnagi.2023.1134472.","journal-title":"Front Aging Neurosci"},{"key":"445_CR112","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1007\/s00702-022-02465-w","volume":"129","author":"WH Jost","year":"2022","unstructured":"Jost WH. A critical appraisal of MAO-B inhibitors in the treatment of Parkinson\u2019s disease. J Neural Transm Vienna Austria 1996. 2022;129:723\u201336. https:\/\/doi.org\/10.1007\/s00702-022-02465-w.","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"445_CR113","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40264-023-01288-2","volume":"46","author":"W Su","year":"2023","unstructured":"Su W, Liang Z, Mao W, Shao M, Hu X, Wu Y, et al. Safety and effectiveness of rasagiline in Chinese patients with Parkinson\u2019s Disease: a prospective, multicenter, non-interventional post-marketing study. Drug Saf. 2023;46:637\u201346. https:\/\/doi.org\/10.1007\/s40264-023-01288-2.","journal-title":"Drug Saf"},{"key":"445_CR114","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.brainresbull.2020.12.018","volume":"168","author":"H Wasan","year":"2021","unstructured":"Wasan H, Singh D, Kh R. Safinamide in neurological disorders and beyond: evidence from preclinical and clinical studies. Brain Res Bull. 2021;168:165\u201377. https:\/\/doi.org\/10.1016\/j.brainresbull.2020.12.018.","journal-title":"Brain Res Bull"},{"key":"445_CR115","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41531-022-00277-z","volume":"8","author":"F Stocchi","year":"2022","unstructured":"Stocchi F, Antonini A, Berg D, Bergmans B, Jost W, Katzenschlager R, et al. Safinamide in the treatment pathway of Parkinson\u2019s disease: a European Delphi Consensus. NPJ Park Dis. 2022;8:17. https:\/\/doi.org\/10.1038\/s41531-022-00277-z.","journal-title":"NPJ Park Dis"},{"key":"445_CR116","doi-asserted-by":"publisher","first-page":"2507","DOI":"10.2147\/DDDT.S302673","volume":"15","author":"G Abbruzzese","year":"2021","unstructured":"Abbruzzese G, Barone P, Lopiano L, Stocchi F. The current evidence for the use of safinamide for the treatment of Parkinson\u2019s Disease. Drug Des Devel Ther. 2021;15:2507\u201317. https:\/\/doi.org\/10.2147\/DDDT.S302673.","journal-title":"Drug Des Devel Ther"},{"key":"445_CR117","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1080\/14656566.2022.2060738","volume":"23","author":"A Salamon","year":"2022","unstructured":"Salamon A, Z\u00e1dori D, Szpisjak L, Kliv\u00e9nyi P, V\u00e9csei L. What is the impact of catechol-O-methyltransferase (COMT) on Parkinson\u2019s disease treatment? Expert Opin Pharmacother. 2022;23:1123\u20138. https:\/\/doi.org\/10.1080\/14656566.2022.2060738.","journal-title":"Expert Opin Pharmacother"},{"key":"445_CR118","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00702-023-02623-8","volume":"130","author":"M Regensburger","year":"2023","unstructured":"Regensburger M, Ip CW, Kohl Z, Schrader C, Urban PP, Kassubek J, et al. Clinical benefit of MAO-B and COMT inhibition in Parkinson\u2019s disease: practical considerations. J Neural Transm Vienna Austria 1996. 2023;130:847\u201361. https:\/\/doi.org\/10.1007\/s00702-023-02623-8.","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"445_CR119","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1007\/s00228-020-03081-x","volume":"77","author":"CA Artusi","year":"2021","unstructured":"Artusi CA, Sarro L, Imbalzano G, Fabbri M, Lopiano L. Safety and efficacy of tolcapone in Parkinson\u2019s disease: systematic review. Eur J Clin Pharmacol. 2021;77:817\u201329. https:\/\/doi.org\/10.1007\/s00228-020-03081-x.","journal-title":"Eur J Clin Pharmacol"},{"key":"445_CR120","doi-asserted-by":"publisher","first-page":"707723","DOI":"10.3389\/fneur.2021.707723","volume":"12","author":"Z Song","year":"2021","unstructured":"Song Z, Zhang J, Xue T, Yang Y, Wu D, Chen Z, et al. Different Catechol-O-Methyl Transferase Inhibitors in Parkinson\u2019s Disease: a Bayesian network meta-analysis. Front Neurol. 2021;12:707723. https:\/\/doi.org\/10.3389\/fneur.2021.707723.","journal-title":"Front Neurol"},{"issue":"2","key":"445_CR121","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1111\/ene.15992","volume":"30","author":"H Reichmann","year":"2023","unstructured":"Reichmann H. Real-world considerations regarding the use of the combination of levodopa, carbidopa, and entacapone (Stalevo\u00ae ) in Parkinson\u2019s disease. Eur J Neurol. 2023;30(2):15\u201320. https:\/\/doi.org\/10.1111\/ene.15992.","journal-title":"Eur J Neurol"},{"issue":"2","key":"445_CR122","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1111\/ene.15993","volume":"30","author":"W Poewe","year":"2023","unstructured":"Poewe W. Catechol-O-methyltransferase inhibition with entacapone: evidence from controlled clinical trials in Parkinson\u2019s disease. Eur J Neurol. 2023;30(2):9\u201314. https:\/\/doi.org\/10.1111\/ene.15993.","journal-title":"Eur J Neurol"},{"key":"445_CR123","doi-asserted-by":"publisher","first-page":"2035","DOI":"10.1007\/s10072-023-07233-6","volume":"45","author":"M Bologna","year":"2024","unstructured":"Bologna M, Guerra A, Colella D, Birreci D, Costa D, Cannavacciuolo A, et al. Objective assessment of the effects of opicapone in Parkinson\u2019s disease through kinematic analysis. Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol. 2024;45:2035\u201346. https:\/\/doi.org\/10.1007\/s10072-023-07233-6.","journal-title":"Neurol Sci Off J Ital Neurol Soc Ital Soc Clin Neurophysiol"},{"key":"445_CR124","doi-asserted-by":"publisher","first-page":"36074","DOI":"10.52965\/001c.36074","volume":"10","author":"AA Berger","year":"2022","unstructured":"Berger AA, Winnick A, Izygon J, Jacob BM, Kaye JS, Kaye RJ, et al. Opicapone, a novel catechol-o-methyl transferase inhibitor, for treatment of Parkinson\u2019s Disease \u201cOff\u201d Episodes. Health Psychol Res. 2022;10:36074. https:\/\/doi.org\/10.52965\/001c.36074.","journal-title":"Health Psychol Res"},{"key":"445_CR125","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1080\/00207454.2021.1929217","volume":"133","author":"M Feldman","year":"2023","unstructured":"Feldman M, Margolesky J. Opicapone for the treatment of Parkinson\u2019s disease: a review. Int J Neurosci. 2023;133:532\u201343. https:\/\/doi.org\/10.1080\/00207454.2021.1929217.","journal-title":"Int J Neurosci"},{"key":"445_CR126","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s40120-021-00246-3","volume":"10","author":"SH Mehta","year":"2021","unstructured":"Mehta SH, Pahwa R, Tanner CM, Hauser RA, Johnson R. Effects of Gocovri (Amantadine) extended release capsules on non-motor symptoms in patients with Parkinson\u2019s disease and dyskinesia. Neurol Ther. 2021;10:307\u201320. https:\/\/doi.org\/10.1007\/s40120-021-00246-3.","journal-title":"Neurol Ther"},{"key":"445_CR127","doi-asserted-by":"publisher","first-page":"739","DOI":"10.1007\/s40120-021-00256-1","volume":"10","author":"RA Hauser","year":"2021","unstructured":"Hauser RA, Mehta SH, Kremens D, Chernick D, Formella AE. Effects of Gocovri (Amantadine) extended-release capsules on motor aspects of experiences of daily living in people with Parkinson\u2019s disease and dyskinesia. Neurol Ther. 2021;10:739\u201351. https:\/\/doi.org\/10.1007\/s40120-021-00256-1.","journal-title":"Neurol Ther"},{"key":"445_CR128","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1038\/s41531-022-00291-1","volume":"8","author":"RA Hauser","year":"2022","unstructured":"Hauser RA, Lytle J, Formella AE, Tanner CM. Amantadine delayed release\/extended release capsules significantly reduce OFF time in Parkinson\u2019s disease. NPJ Park Dis. 2022;8:29. https:\/\/doi.org\/10.1038\/s41531-022-00291-1.","journal-title":"NPJ Park Dis"},{"key":"445_CR129","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/s41531-025-01187-6","volume":"11","author":"X An","year":"2025","unstructured":"An X, Su L, Yang Q, Shen B, Gan L, Jun Ji J, et al. A spatiotemporal hypergraph self-attention neural networks framework for the identification and pharmacological efficacy assessment of Parkinson\u2019s disease motor symptoms. NPJ Park Dis. 2025;11:338. https:\/\/doi.org\/10.1038\/s41531-025-01187-6.","journal-title":"NPJ Park Dis"},{"key":"445_CR130","doi-asserted-by":"publisher","first-page":"e001115","DOI":"10.1136\/bmjno-2025-001115","volume":"7","author":"S Rujirussawarawong","year":"2025","unstructured":"Rujirussawarawong S, Aungsumart S, Kasemsuk C, Limotai N. Efficacy and safety of oral amantadine in Parkinson\u2019s disease with dyskinesia and motor fluctuations: a systematic review and meta-analysis of randomised controlled trials. BMJ Neurol Open. 2025;7:e001115. https:\/\/doi.org\/10.1136\/bmjno-2025-001115.","journal-title":"BMJ Neurol Open"},{"key":"445_CR131","doi-asserted-by":"publisher","first-page":"a041642","DOI":"10.1101\/cshperspect.a041642","volume":"15","author":"CG Goetz","year":"2025","unstructured":"Goetz CG. Historical perspectives of Parkinson\u2019s disease: early clinical descriptions and neurological therapies. Cold Spring Harb Perspect Med. 2025;15:a041642. https:\/\/doi.org\/10.1101\/cshperspect.a041642.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"445_CR132","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s40263-024-01078-z","volume":"38","author":"N Vanegas-Arroyave","year":"2024","unstructured":"Vanegas-Arroyave N, Caroff SN, Citrome L, Crasta J, McIntyre RS, Meyer JM, et al. An evidence-based update on anticholinergic use for drug-induced movement disorders. CNS Drugs. 2024;38:239\u201354. https:\/\/doi.org\/10.1007\/s40263-024-01078-z.","journal-title":"CNS Drugs"},{"key":"445_CR133","doi-asserted-by":"publisher","first-page":"405","DOI":"10.5603\/PJNNS.a2023.0041","volume":"57","author":"JJ Malkiewicz","year":"2023","unstructured":"Malkiewicz JJ, Kasprzyk AG, Waksmundzki D, W\u0119grzynek J, Chmiela T, Siuda J. Risk factors for dementia in Parkinson\u2019s disease - the overuse of anticholinergic drugs. Neurol Neurochir Pol. 2023;57:405\u201313. https:\/\/doi.org\/10.5603\/PJNNS.a2023.0041.","journal-title":"Neurol Neurochir Pol"},{"key":"445_CR134","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3233\/JPD-225060","volume":"13","author":"W Pirker","year":"2023","unstructured":"Pirker W, Katzenschlager R, Hallett M, Poewe W. Pharmacological treatment of tremor in parkinson\u2019s disease revisited. J Park Dis. 2023;13:127\u201344. https:\/\/doi.org\/10.3233\/JPD-225060.","journal-title":"J Park Dis"},{"key":"445_CR135","doi-asserted-by":"publisher","first-page":"300","DOI":"10.1007\/s00415-022-11342-1","volume":"270","author":"I Waggan","year":"2023","unstructured":"Waggan I, Rissanen E, Tuisku J, Joutsa J, Helin S, Parkkola R, et al. Adenosine A2A receptor availability in patients with early- and moderate-stage Parkinson\u2019s disease. J Neurol. 2023;270:300\u201310. https:\/\/doi.org\/10.1007\/s00415-022-11342-1.","journal-title":"J Neurol"},{"key":"445_CR136","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.3390\/molecules27072366","volume":"27","author":"A Mori","year":"2022","unstructured":"Mori A, Chen J-F, Uchida S, Durlach C, King SM, Jenner P. The pharmacological potential of adenosine A2A receptor antagonists for treating Parkinson\u2019s disease. Mol Basel Switz. 2022;27:2366. https:\/\/doi.org\/10.3390\/molecules27072366.","journal-title":"Mol Basel Switz"},{"key":"445_CR137","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2147\/DNND.S245197","volume":"12","author":"SH Isaacson","year":"2022","unstructured":"Isaacson SH, Bett\u00e9 S, Pahwa R. Istradefylline for OFF episodes in Parkinson\u2019s disease: a us perspective of common clinical scenarios. Degener Neurol Neuromuscul Dis. 2022;12:97\u2013109. https:\/\/doi.org\/10.2147\/DNND.S245197.","journal-title":"Degener Neurol Neuromuscul Dis"},{"key":"445_CR138","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1038\/s41531-023-00589-8","volume":"9","author":"W Sako","year":"2023","unstructured":"Sako W, Kogo Y, Koebis M, Kita Y, Yamakage H, Ishida T, et al. Comparative efficacy and safety of adjunctive drugs to levodopa for fluctuating Parkinson\u2019s disease - network meta-analysis. NPJ Park Dis. 2023;9:143. https:\/\/doi.org\/10.1038\/s41531-023-00589-8.","journal-title":"NPJ Park Dis"},{"key":"445_CR139","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/S1474-4422(18)30496-4","volume":"18","author":"O Rascol","year":"2019","unstructured":"Rascol O. CVT-301 for Parkinson\u2019s disease: dose and effect size issues. Lancet Neurol. 2019;18:128\u201330. https:\/\/doi.org\/10.1016\/S1474-4422(18)30496-4.","journal-title":"Lancet Neurol"},{"key":"445_CR140","doi-asserted-by":"publisher","first-page":"1559","DOI":"10.1080\/17425247.2021.1960820","volume":"18","author":"MM Lipp","year":"2021","unstructured":"Lipp MM, Hickey JA, Langer R, LeWitt AP. A technology evaluation of CVT-301 (Inbrija): an inhalable therapy for treatment of Parkinson\u2019s disease. Expert Opin Drug Deliv. 2021;18:1559\u201369. https:\/\/doi.org\/10.1080\/17425247.2021.1960820.","journal-title":"Expert Opin Drug Deliv"},{"key":"445_CR141","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1212\/CPJ.0000000000001143","volume":"12","author":"G Glenardi","year":"2022","unstructured":"Glenardi G, Handayani T, Barus J, Mangkuliguna G. Inhaled Levodopa (CVT-301) for the treatment of parkinson disease: a systematic review and meta-analysis of randomized controlled trials. Neurol Clin Pract. 2022;12:139\u201348. https:\/\/doi.org\/10.1212\/CPJ.0000000000001143.","journal-title":"Neurol Clin Pract"},{"key":"445_CR142","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1007\/s00702-023-02636-3","volume":"130","author":"HW Jost","year":"2023","unstructured":"Jost HW, Kulisevsky J, LeWitt AP. Inhaled levodopa for threatening impending OFF episodes in managing Parkinson\u2019s disease. J Neural Transm Vienna Austria 1996. 2023;130:821\u20136. https:\/\/doi.org\/10.1007\/s00702-023-02636-3.","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"445_CR143","doi-asserted-by":"publisher","DOI":"10.1007\/s00702-025-02911-5","author":"T Koeglsperger","year":"2025","unstructured":"Koeglsperger T, Berberovic E, Dresel C, Haferkamp S, Kassubek J, M\u00fcller R, et al. Real-world experience with continuous subcutaneous foslevodopa\/foscarbidopa infusion: insights and recommendations. J Neural Transm. 2025. https:\/\/doi.org\/10.1007\/s00702-025-02911-5.","journal-title":"J Neural Transm"},{"key":"445_CR144","doi-asserted-by":"publisher","first-page":"2071","DOI":"10.3233\/JPD-223295","volume":"12","author":"RK Chaudhuri","year":"2022","unstructured":"Chaudhuri RK, Antonini A, Pahwa R, Odin P, Titova N, Thakkar S, et al. Effects of levodopa-carbidopa intestinal gel on dyskinesia and non-motor symptoms including sleep: results from a meta-analysis with 24-month follow-up. J Parkinsons Dis. 2022;12:2071\u201383. https:\/\/doi.org\/10.3233\/JPD-223295.","journal-title":"J Parkinsons Dis"},{"key":"445_CR145","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.3390\/biomedicines13092191","volume":"13","author":"M Lungu","year":"2025","unstructured":"Lungu M, Oprea DV, Apostol LL, Elkan ME, Ionescu MA, Tudor A, et al. Levodopa-carbidopa-entacapone intestinal gel for advanced Parkinson\u2019s disease-results from a monocentric study evaluating both motor and non-motor manifestations. Biomedicines. 2025;13:2191. https:\/\/doi.org\/10.3390\/biomedicines13092191.","journal-title":"Biomedicines"},{"key":"445_CR146","doi-asserted-by":"publisher","first-page":"e941285","DOI":"10.12659\/MSM.941285","volume":"29","author":"Y Nomoto","year":"2023","unstructured":"Nomoto Y, Furihata M, Hagiwara H, Ishino H, Yano S, Okawa H, et al. Transgastric Jejunostomy (PEG-J) for continuous infusion of levodopa-carbidopa intestinal gel: an approach for Parkinson\u2019s disease treatment. Med Sci Monit Int Med J Exp Clin Res. 2023;29:e941285. https:\/\/doi.org\/10.12659\/MSM.941285.","journal-title":"Med Sci Monit Int Med J Exp Clin Res"},{"key":"445_CR147","doi-asserted-by":"publisher","first-page":"769","DOI":"10.3233\/JPD-225105","volume":"13","author":"RK Chaudhuri","year":"2023","unstructured":"Chaudhuri RK, Kov\u00e1cs N, Pontieri EF, Aldred J, Bourgeois P, Davis LT, et al. Levodopa carbidopa intestinal gel in advanced Parkinson\u2019s disease: DUOGLOBE final 3-year results. J Park Dis. 2023;13:769\u201383. https:\/\/doi.org\/10.3233\/JPD-225105.","journal-title":"J Park Dis"},{"key":"445_CR148","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1017\/cjn.2023.251","volume":"51","author":"C Vekhande","year":"2024","unstructured":"Vekhande C, Hamed M, Tremain G, Mah J, Shetty A, Lazarescu A, et al. Levodopa-Carbidopa Intestinal Gel for Parkinson\u2019s Disease over 11 years: One Center\u2019s \u201cReal-World\u201d Experience. Can J Neurol Sci J Can Sci Neurol. 2024;51:379\u201386. https:\/\/doi.org\/10.1017\/cjn.2023.251.","journal-title":"Can J Neurol Sci J Can Sci Neurol"},{"key":"445_CR149","doi-asserted-by":"publisher","unstructured":"Yu JRT, Kundrick A, Panganiban EC, Sy MA, Anis S, Fernandez HH. Therapeutic innovations for the symptomatic treatment of Parkinson\u2019s disease: focus on technology-based therapies. J Neural Transm Vienna Austria 1996. 2025. https:\/\/doi.org\/10.1007\/s00702-025-02915-1.","DOI":"10.1007\/s00702-025-02915-1"},{"key":"445_CR150","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1038\/s41531-021-00194-7","volume":"7","author":"B Meira","year":"2021","unstructured":"Meira B, Degos B, Corsetti E, Doulazmi M, Berthelot E, Virbel-Fleischman C, et al. Long-term effect of apomorphine infusion in advanced Parkinson\u2019s disease: a real-life study. NPJ Parkinsons Dis. 2021;7:50. https:\/\/doi.org\/10.1038\/s41531-021-00194-7.","journal-title":"NPJ Parkinsons Dis"},{"key":"445_CR151","doi-asserted-by":"publisher","first-page":"107950","DOI":"10.1016\/j.parkreldis.2025.107950","volume":"138","author":"M Garon","year":"2025","unstructured":"Garon M, Scharfenort M, Antonini A, Odin P, Ljung H. Cognitive outcomes of infusion therapies in Parkinson\u2019s disease: a comprehensive systematic review. Parkinsonism Relat Disord. 2025;138:107950. https:\/\/doi.org\/10.1016\/j.parkreldis.2025.107950.","journal-title":"Parkinsonism Relat Disord"},{"key":"445_CR152","doi-asserted-by":"publisher","unstructured":"Santos-Garc\u00eda D, Solleiro \u00c1, Gonz\u00e1lez-Ortega G, Mir P, L\u00f3pez-Ariztegui N, Legarda I, et al. Impact of device-aided therapies on quality of life in patients with Parkinson\u2019s disease. A comparative multicenter observational study. J Neural Transm Vienna Austria 1996. 2025. https:\/\/doi.org\/10.1007\/s00702-025-03066-z.","DOI":"10.1007\/s00702-025-03066-z"},{"key":"445_CR153","doi-asserted-by":"publisher","first-page":"114","DOI":"10.1038\/s41531-023-00552-7","volume":"9","author":"DL Price","year":"2023","unstructured":"Price DL, Khan A, Angers R, Cardenas A, Prato MK, Bani M, et al. In vivo effects of the alpha-synuclein misfolding inhibitor minzasolmin supports clinical development in Parkinson\u2019s disease. NPJ Park Dis. 2023;9:114. https:\/\/doi.org\/10.1038\/s41531-023-00552-7.","journal-title":"NPJ Park Dis"},{"key":"445_CR154","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1007\/s11307-023-01878-7","volume":"26","author":"J Mercier","year":"2024","unstructured":"Mercier J, Bani M, Colson A-O, Germani M, Lalla M, Plisson C, et al. Evaluation and Application of a PET Tracer in Preclinical and Phase 1 Studies to Determine the Brain Biodistribution of Minzasolmin (UCB0599). Mol Imaging Biol. 2024;26:310\u201321. https:\/\/doi.org\/10.1007\/s11307-023-01878-7.","journal-title":"Mol Imaging Biol"},{"key":"445_CR155","doi-asserted-by":"publisher","first-page":"16165","DOI":"10.1038\/s41598-018-34490-9","volume":"8","author":"DL Price","year":"2018","unstructured":"Price DL, Koike MA, Khan A, Wrasidlo W, Rockenstein E, Masliah E, et al. The small molecule alpha-synuclein misfolding inhibitor, NPT200-11, produces multiple benefits in an animal model of Parkinson\u2019s disease. Sci Rep. 2018;8:16165. https:\/\/doi.org\/10.1038\/s41598-018-34490-9.","journal-title":"Sci Rep"},{"key":"445_CR156","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1002\/mds.29170","volume":"37","author":"JW Smit","year":"2022","unstructured":"Smit JW, Basile P, Prato MK, Detalle L, Mathy F-X, Schmidt A, et al. Phase 1\/1b studies of UCB0599, an oral inhibitor of \u03b1-Synuclein misfolding, including a randomized study in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2022;37:2045\u201356. https:\/\/doi.org\/10.1002\/mds.29170.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"445_CR157","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1002\/mds.28858","volume":"37","author":"MH Werner","year":"2022","unstructured":"Werner MH, Olanow CW. Parkinson\u2019s disease modification through Abl kinase inhibition: an opportunity. Mov Disord Off J Mov Disord Soc. 2022;37:6\u201315. https:\/\/doi.org\/10.1002\/mds.28858.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"445_CR158","doi-asserted-by":"publisher","first-page":"108025","DOI":"10.1016\/j.intimp.2021.108025","volume":"99","author":"J Wu","year":"2021","unstructured":"Wu J, Xu X, Zheng L, Mo J, Jin X, Bao Y. Nilotinib inhibits microglia-mediated neuroinflammation to protect against dopaminergic neuronal death in Parkinson\u2019s disease models. Int Immunopharmacol. 2021;99:108025. https:\/\/doi.org\/10.1016\/j.intimp.2021.108025.","journal-title":"Int Immunopharmacol"},{"key":"445_CR159","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1001\/jamaneurol.2019.4200","volume":"77","author":"FL Pagan","year":"2020","unstructured":"Pagan FL, Hebron ML, Wilmarth B, Torres-Yaghi Y, Lawler A, Mundel EE, et al. Nilotinib effects on safety, tolerability, and potential biomarkers in Parkinson disease: a phase 2 randomized clinical trial. JAMA Neurol. 2020;77:309\u201317. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4200.","journal-title":"JAMA Neurol"},{"key":"445_CR160","doi-asserted-by":"publisher","first-page":"105281","DOI":"10.1016\/j.parkreldis.2023.105281","volume":"108","author":"RR Walsh","year":"2023","unstructured":"Walsh RR, Damle NK, Mandhane S, Piccoli SP, Talluri RS, Love D, et al. Plasma and cerebrospinal fluid pharmacokinetics of vodobatinib, a neuroprotective c-Abl tyrosine kinase inhibitor for the treatment of Parkinson\u2019s disease. Parkinsonism Relat Disord. 2023;108:105281. https:\/\/doi.org\/10.1016\/j.parkreldis.2023.105281.","journal-title":"Parkinsonism Relat Disord"},{"key":"445_CR161","doi-asserted-by":"publisher","first-page":"eabp9352","DOI":"10.1126\/scitranslmed.abp9352","volume":"15","author":"SS Karuppagounder","year":"2023","unstructured":"Karuppagounder SS, Wang H, Kelly T, Rush R, Nguyen R, Bisen S, et al. The c-Abl inhibitor IkT-148009 suppresses neurodegeneration in mouse models of heritable and sporadic Parkinson\u2019s disease. Sci Transl Med. 2023;15:eabp9352. https:\/\/doi.org\/10.1126\/scitranslmed.abp9352.","journal-title":"Sci Transl Med"},{"key":"445_CR162","doi-asserted-by":"publisher","first-page":"325","DOI":"10.3233\/JPD-230319","volume":"14","author":"MH Werner","year":"2024","unstructured":"Werner MH, Olanow CW, McGarry A, Meyer C, Kruger S, Klint C, et al. A phase I, randomized, SAD, MAD, and PK study of Risvodetinib in older adults and Parkinson\u2019s disease. J Parkinsons Dis. 2024;14:325\u201334. https:\/\/doi.org\/10.3233\/JPD-230319.","journal-title":"J Parkinsons Dis"},{"key":"445_CR163","doi-asserted-by":"publisher","first-page":"100645","DOI":"10.1016\/j.medj.2025.100645","volume":"6","author":"BR Bloem","year":"2025","unstructured":"Bloem BR, Macklin EA, Schwarzschild MA. GLP-1 agonists to slow down Parkinson\u2019s progression? The quest continues. Med N Y N. 2025;6:100645. https:\/\/doi.org\/10.1016\/j.medj.2025.100645.","journal-title":"Med N Y N"},{"key":"445_CR164","doi-asserted-by":"publisher","first-page":"955258","DOI":"10.3389\/fnsyn.2022.955258","volume":"14","author":"C H\u00f6lscher","year":"2022","unstructured":"H\u00f6lscher C. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer\u2019s and Parkinson\u2019s diseases. Front Synaptic Neurosci. 2022;14:955258. https:\/\/doi.org\/10.3389\/fnsyn.2022.955258.","journal-title":"Front Synaptic Neurosci"},{"key":"445_CR165","doi-asserted-by":"publisher","first-page":"111529","DOI":"10.1016\/j.mce.2021.111529","volume":"542","author":"M Zhang","year":"2022","unstructured":"Zhang M, Wu Y, Gao R, Chen X, Chen R, Chen Z. Glucagon-like peptide-1 analogs mitigate neuroinflammation in Alzheimer\u2019s disease by suppressing NLRP2 activation in astrocytes. Mol Cell Endocrinol. 2022;542:111529. https:\/\/doi.org\/10.1016\/j.mce.2021.111529.","journal-title":"Mol Cell Endocrinol"},{"key":"445_CR166","doi-asserted-by":"publisher","first-page":"962","DOI":"10.1007\/s13311-021-01018-5","volume":"18","author":"L-L Bu","year":"2021","unstructured":"Bu L-L, Liu Y-Q, Shen Y, Fan Y, Yu W-B, Jiang D-L, et al. Neuroprotection of Exendin-4 by enhanced autophagy in a parkinsonian rat model of \u03b1-Synucleinopathy. Neurother J Am Soc Exp Neurother. 2021;18:962\u201378. https:\/\/doi.org\/10.1007\/s13311-021-01018-5.","journal-title":"Neurother J Am Soc Exp Neurother"},{"key":"445_CR167","doi-asserted-by":"publisher","first-page":"665","DOI":"10.2147\/DDDT.S348055","volume":"16","author":"D Cheng","year":"2022","unstructured":"Cheng D, Yang S, Zhao X, Wang G. The role of glucagon-like peptide-1 receptor agonists (GLP-1 RA) in diabetes-related neurodegenerative diseases. Drug Des Devel Ther. 2022;16:665\u201384. https:\/\/doi.org\/10.2147\/DDDT.S348055.","journal-title":"Drug Des Devel Ther"},{"key":"445_CR168","doi-asserted-by":"publisher","first-page":"825","DOI":"10.3390\/jpm12050825","volume":"12","author":"C-C Wu","year":"2022","unstructured":"Wu C-C, Islam MM, Lee A-J, Su C-H, Weng Y-C, Yeh C-Y, et al. Association between statin use and risk of Parkinson\u2019s disease: evidence from 18 observational studies comprising 3.7 million individuals. J Pers Med. 2022;12:825. https:\/\/doi.org\/10.3390\/jpm12050825.","journal-title":"J Pers Med"},{"key":"445_CR169","doi-asserted-by":"publisher","first-page":"e01063","DOI":"10.1002\/prp2.1063","volume":"11","author":"HM Al-Kuraishy","year":"2023","unstructured":"Al-Kuraishy HM, Al-Gareeb AI, Alexiou A, Papadakis M, Alsayegh AA, Almohmadi NH, et al. Pros and cons for statins use and risk of Parkinson\u2019s disease: an updated perspective. Pharmacol Res Perspect. 2023;11:e01063. https:\/\/doi.org\/10.1002\/prp2.1063.","journal-title":"Pharmacol Res Perspect"},{"key":"445_CR170","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1002\/mds.28474","volume":"36","author":"C-H Lin","year":"2021","unstructured":"Lin C-H, Chang C-H, Tai C-H, Cheng M-F, Chen Y-C, Chao Y-T, et al. A double-blind, randomized, controlled trial of lovastatin in early-stage parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2021;36:1229\u201337. https:\/\/doi.org\/10.1002\/mds.28474.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"445_CR171","doi-asserted-by":"publisher","first-page":"10414","DOI":"10.3390\/ijms241310414","volume":"24","author":"M Rubio-Osornio","year":"2023","unstructured":"Rubio-Osornio M, Le\u00f3n CTG-D, Montes S, Rubio C, R\u00edos C, Monroy A, et al. Repurposing simvastatin in Parkinson\u2019s disease model: protection is throughout modulation of the neuro-inflammatory response in the substantia Nigra. Int J Mol Sci. 2023;24:10414. https:\/\/doi.org\/10.3390\/ijms241310414.","journal-title":"Int J Mol Sci"},{"key":"445_CR172","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1001\/jamaneurol.2022.3718","volume":"79","author":"KN Stevens","year":"2022","unstructured":"Stevens KN, Creanor S, Jeffery A, Whone A, Zajicek J, Foggo A, et al. Evaluation of simvastatin as a disease-modifying treatment for patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2022;79:1232\u201341. https:\/\/doi.org\/10.1001\/jamaneurol.2022.3718.","journal-title":"JAMA Neurol"},{"key":"445_CR173","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s00702-023-02630-9","volume":"130","author":"P Riederer","year":"2023","unstructured":"Riederer P, Nagatsu T, Youdim MBH, Wulf M, Dijkstra JM, Sian-Huelsmann J. Lewy bodies, iron, inflammation and neuromelanin: pathological aspects underlying Parkinson\u2019s disease. J Neural Transm Vienna Austria 1996. 2023;130:627\u201346. https:\/\/doi.org\/10.1007\/s00702-023-02630-9.","journal-title":"J Neural Transm Vienna Austria 1996"},{"key":"445_CR174","doi-asserted-by":"publisher","first-page":"102477","DOI":"10.1016\/j.arr.2024.102477","volume":"101","author":"Z Yao","year":"2024","unstructured":"Yao Z, Jiao Q, Du X, Jia F, Chen X, Yan C, et al. Ferroptosis in Parkinson\u2019s disease -- the iron-related degenerative disease. Ageing Res Rev. 2024;101:102477. https:\/\/doi.org\/10.1016\/j.arr.2024.102477.","journal-title":"Ageing Res Rev"},{"key":"445_CR175","doi-asserted-by":"publisher","first-page":"1256","DOI":"10.3390\/ijms24021256","volume":"24","author":"A Gonzalez-Alcocer","year":"2023","unstructured":"Gonzalez-Alcocer A, Duarte-Jurado AP, Soto-Dominguez A, Loera-Arias MdeJ, Villarreal-Silva EE, Saucedo-Cardenas O, et al. Unscrambling the role of redox-active biometals in dopaminergic neuronal death and promising metal chelation-based therapy for Parkinson\u2019s disease. Int J Mol Sci. 2023;24:1256. https:\/\/doi.org\/10.3390\/ijms24021256.","journal-title":"Int J Mol Sci"},{"key":"445_CR176","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1177\/1877718X241300295","volume":"15","author":"D Devos","year":"2025","unstructured":"Devos D, Rascol O, Meissner WG, Foubert-Samier A, Lewis S, Tranchant C, et al. Therapeutic modalities of deferiprone in Parkinson\u2019s disease: SKY and EMBARK studies. J Park Dis. 2025;15:72\u201386. https:\/\/doi.org\/10.1177\/1877718X241300295.","journal-title":"J Park Dis"},{"key":"445_CR177","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1056\/NEJMoa2209254","volume":"387","author":"D Devos","year":"2022","unstructured":"Devos D, Labreuche J, Rascol O, Corvol J-C, Duhamel A, Guyon Delannoy P, et al. Trial of deferiprone in Parkinson\u2019s disease. N Engl J Med. 2022;387:2045\u201355. https:\/\/doi.org\/10.1056\/NEJMoa2209254.","journal-title":"N Engl J Med"},{"key":"445_CR178","doi-asserted-by":"publisher","first-page":"e14607","DOI":"10.1111\/cns.14607","volume":"30","author":"A Negida","year":"2024","unstructured":"Negida A, Hassan NM, Aboeldahab H, Zain YE, Negida Y, Cadri S, et al. Efficacy of the iron-chelating agent, deferiprone, in patients with Parkinson\u2019s disease: a systematic review and meta-analysis. CNS Neurosci Ther. 2024;30:e14607. https:\/\/doi.org\/10.1111\/cns.14607.","journal-title":"CNS Neurosci Ther"},{"key":"445_CR179","doi-asserted-by":"publisher","first-page":"2396","DOI":"10.1093\/hmg\/ddac038","volume":"31","author":"SY Yang","year":"2022","unstructured":"Yang SY, Taanman JW, Gegg M, Schapira AHV. Ambroxol reverses tau and \u03b1-synuclein accumulation in a cholinergic N370S GBA1 mutation model. Hum Mol Genet. 2022;31:2396\u2013405. https:\/\/doi.org\/10.1093\/hmg\/ddac038.","journal-title":"Hum Mol Genet"},{"key":"445_CR180","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1001\/jamaneurol.2019.4611","volume":"77","author":"S Mullin","year":"2020","unstructured":"Mullin S, Smith L, Lee K, D\u2019Souza G, Woodgate P, Elflein J, et al. Ambroxol for the treatment of patients with Parkinson disease with and without glucocerebrosidase gene mutations: a nonrandomized, noncontrolled trial. JAMA Neurol. 2020;77:427\u201334. https:\/\/doi.org\/10.1001\/jamaneurol.2019.4611.","journal-title":"JAMA Neurol"},{"key":"445_CR181","doi-asserted-by":"publisher","first-page":"e000535","DOI":"10.1136\/bmjno-2023-000535","volume":"5","author":"F Colucci","year":"2023","unstructured":"Colucci F, Avenali M, De Micco R, Fusar Poli M, Cerri S, Stanziano M, et al. Ambroxol as a disease-modifying treatment to reduce the risk of cognitive impairment in GBA-associated Parkinson\u2019s disease: a multicentre, randomised, double-blind, placebo-controlled, phase II trial. The AMBITIOUS study protocol. BMJ Neurol Open. 2023;5:e000535. https:\/\/doi.org\/10.1136\/bmjno-2023-000535.","journal-title":"BMJ Neurol Open"},{"key":"445_CR182","doi-asserted-by":"publisher","first-page":"1077","DOI":"10.1016\/j.molmed.2025.03.008","volume":"31","author":"H McHale-Owen","year":"2025","unstructured":"McHale-Owen H, Faller KME, Chaytow H, Gillingwater TH. Phosphoglycerate kinase 1 as a therapeutic target in neurological disease. Trends Mol Med. 2025;31:1077\u201388. https:\/\/doi.org\/10.1016\/j.molmed.2025.03.008.","journal-title":"Trends Mol Med"},{"key":"445_CR183","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1172\/JCI129987","volume":"129","author":"R Cai","year":"2019","unstructured":"Cai R, Zhang Y, Simmering JE, Schultz JL, Li Y, Fernandez-Carasa I, et al. Enhancing glycolysis attenuates Parkinson\u2019s disease progression in models and clinical databases. J Clin Invest. 2019;129:4539\u201349. https:\/\/doi.org\/10.1172\/JCI129987.","journal-title":"J Clin Invest"},{"key":"445_CR184","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1001\/jamaneurol.2020.5157","volume":"78","author":"JE Simmering","year":"2021","unstructured":"Simmering JE, Welsh MJ, Liu L, Narayanan NS, Potteg\u00e5rd A. Association of glycolysis-enhancing \u03b1-1 blockers with risk of developing Parkinson disease. JAMA Neurol. 2021;78:407\u201313. https:\/\/doi.org\/10.1001\/jamaneurol.2020.5157.","journal-title":"JAMA Neurol"},{"key":"445_CR185","doi-asserted-by":"publisher","first-page":"2210","DOI":"10.1002\/mds.29184","volume":"37","author":"JE Simmering","year":"2022","unstructured":"Simmering JE, Welsh MJ, Schultz J, Narayanan NS. Use of glycolysis-enhancing drugs and risk of Parkinson\u2019s disease. Mov Disord. 2022;37:2210\u20136. https:\/\/doi.org\/10.1002\/mds.29184.","journal-title":"Mov Disord"},{"key":"445_CR186","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1038\/s41531-023-00477-1","volume":"9","author":"MA Weber","year":"2023","unstructured":"Weber MA, Sivakumar K, Tabakovic EE, Oya M, Aldridge GM, Zhang Q, et al. Glycolysis-enhancing \u03b11-adrenergic antagonists modify cognitive symptoms related to Parkinson\u2019s disease. NPJ Park Dis. 2023;9:32. https:\/\/doi.org\/10.1038\/s41531-023-00477-1.","journal-title":"NPJ Park Dis"},{"key":"445_CR187","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1038\/s41401-020-0358-x","volume":"41","author":"J-Q Liu","year":"2020","unstructured":"Liu J-Q, Zhao M, Zhang Z, Cui L-Y, Zhou X, Zhang W, et al. Rg1 improves LPS-induced Parkinsonian symptoms in mice via inhibition of NF-\u03baB signaling and modulation of M1\/M2 polarization. Acta Pharmacol Sin. 2020;41:523\u201334. https:\/\/doi.org\/10.1038\/s41401-020-0358-x.","journal-title":"Acta Pharmacol Sin"},{"key":"445_CR188","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1111\/cbdd.14041","volume":"99","author":"Y Yang","year":"2022","unstructured":"Yang Y, Wang L, Zhang C, Guo Y, Li J, Wu C, et al. Ginsenoside Rg1 improves Alzheimer\u2019s disease by regulating oxidative stress, apoptosis, and neuroinflammation through Wnt\/GSK-3\u03b2\/\u03b2-catenin signaling pathway. Chem Biol Drug Des. 2022;99:884\u201396. https:\/\/doi.org\/10.1111\/cbdd.14041.","journal-title":"Chem Biol Drug Des"},{"key":"445_CR189","doi-asserted-by":"publisher","first-page":"552","DOI":"10.3892\/etm.2021.9984","volume":"21","author":"Y-B He","year":"2021","unstructured":"He Y-B, Liu Y-L, Yang Z-D, Lu J-H, Song Y, Guan Y-M, et al. Effect of ginsenoside-Rg1 on experimental Parkinson\u2019s disease: a systematic review and meta-analysis of animal studies. Exp Ther Med. 2021;21:552. https:\/\/doi.org\/10.3892\/etm.2021.9984.","journal-title":"Exp Ther Med"},{"key":"445_CR190","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1038\/s41401-024-01374-w","volume":"46","author":"S-S Wang","year":"2025","unstructured":"Wang S-S, Peng Y, Fan P-L, Ye J-R, Ma W-Y, Wu Q-L, et al. Ginsenoside Rg1 ameliorates stress-exacerbated Parkinson\u2019s disease in mice by eliminating RTP801 and \u03b1-synuclein autophagic degradation obstacle. Acta Pharmacol Sin. 2025;46:308\u201325. https:\/\/doi.org\/10.1038\/s41401-024-01374-w.","journal-title":"Acta Pharmacol Sin"},{"key":"445_CR191","doi-asserted-by":"publisher","first-page":"396","DOI":"10.3390\/antiox12020396","volume":"12","author":"X Hu","year":"2023","unstructured":"Hu X, Li J, Wang X, Liu H, Wang T, Lin Z, et al. Neuroprotective effect of melatonin on sleep disorders associated with Parkinson\u2019s disease. Antioxid Basel Switz. 2023;12:396. https:\/\/doi.org\/10.3390\/antiox12020396.","journal-title":"Antioxid Basel Switz"},{"key":"445_CR192","doi-asserted-by":"publisher","first-page":"102480","DOI":"10.1016\/j.arr.2024.102480","volume":"101","author":"RJ Reiter","year":"2024","unstructured":"Reiter RJ, Sharma RN, Manucha W, Rosales-Corral S, Almieda Chuffa LGde, Loh D, et al. Dysfunctional mitochondria in age-related neurodegeneration: utility of melatonin as an antioxidant treatment. Ageing Res Rev. 2024;101:102480. https:\/\/doi.org\/10.1016\/j.arr.2024.102480.","journal-title":"Ageing Res Rev"},{"key":"445_CR193","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1002\/med.22117","volume":"45","author":"RFN Ribeiro","year":"2025","unstructured":"Ribeiro RFN, Santos MR, Aquino M, de Almeida LP, Cavadas C, Silva MMC. The therapeutic potential of melatonin and its novel synthetic analogs in circadian rhythm sleep disorders, inflammation-associated pathologies, and neurodegenerative diseases. Med Res Rev. 2025;45:1515\u201339. https:\/\/doi.org\/10.1002\/med.22117.","journal-title":"Med Res Rev"},{"key":"445_CR194","doi-asserted-by":"publisher","DOI":"10.1038\/s41531-022-00352-5","volume":"8","author":"J Li","year":"2022","unstructured":"Li J, Liu H, Wang X, Xia Y, Huang J, Wang T, et al. Melatonin ameliorates Parkinson\u2019s disease via regulating microglia polarization in a ROR\u03b1-dependent pathway. NPJ Park Dis. 2022;8:90. https:\/\/doi.org\/10.1038\/s41531-022-00352-5.","journal-title":"NPJ Park Dis"},{"key":"445_CR195","doi-asserted-by":"publisher","first-page":"3063","DOI":"10.2147\/JIR.S317672","volume":"14","author":"R Zheng","year":"2021","unstructured":"Zheng R, Ruan Y, Yan Y, Lin Z, Xue N, Yan Y, et al. Melatonin attenuates neuroinflammation by down-regulating NLRP3 Inflammasome via a SIRT1-dependent pathway in MPTP-induced models of Parkinson\u2019s DISEASE. J Inflamm Res. 2021;14:3063\u201375. https:\/\/doi.org\/10.2147\/JIR.S317672.","journal-title":"J Inflamm Res"},{"key":"445_CR196","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1016\/j.parkreldis.2020.03.029","volume":"75","author":"JH Ahn","year":"2020","unstructured":"Ahn JH, Kim M, Park S, Jang W, Park J, Oh E, et al. Prolonged-release melatonin in Parkinson\u2019s disease patients with a poor sleep quality: a randomized trial. Parkinsonism Relat Disord. 2020;75:50\u20134. https:\/\/doi.org\/10.1016\/j.parkreldis.2020.03.029.","journal-title":"Parkinsonism Relat Disord"},{"key":"445_CR197","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/s41582-020-00426-z","volume":"17","author":"JK Krauss","year":"2021","unstructured":"Krauss JK, Lipsman N, Aziz T, Boutet A, Brown P, Chang JW, et al. Technology of deep brain stimulation: current status and future directions. Nat Rev Neurol. 2021;17:75\u201387. https:\/\/doi.org\/10.1038\/s41582-020-00426-z.","journal-title":"Nat Rev Neurol"},{"key":"445_CR198","doi-asserted-by":"publisher","first-page":"4456","DOI":"10.1093\/brain\/awad239","volume":"146","author":"W-J Neumann","year":"2023","unstructured":"Neumann W-J, Steiner LA, Milosevic L. Neurophysiological mechanisms of deep brain stimulation across spatiotemporal resolutions. Brain J Neurol. 2023;146:4456\u201368. https:\/\/doi.org\/10.1093\/brain\/awad239.","journal-title":"Brain J Neurol"},{"key":"445_CR199","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1007\/s11065-022-09540-9","volume":"33","author":"M Bucur","year":"2023","unstructured":"Bucur M, Papagno C. Deep brain stimulation in Parkinson disease: a meta-analysis of the long-term neuropsychological outcomes. Neuropsychol Rev. 2023;33:307\u201346. https:\/\/doi.org\/10.1007\/s11065-022-09540-9.","journal-title":"Neuropsychol Rev"},{"key":"445_CR200","doi-asserted-by":"publisher","first-page":"1041449","DOI":"10.3389\/fneur.2022.1041449","volume":"13","author":"P Krause","year":"2022","unstructured":"Krause P, Reimer J, Kaplan J, Borngr\u00e4ber F, Schneider G-H, Faust K, et al. Deep brain stimulation in early onset Parkinson\u2019s disease. Front Neurol. 2022;13:1041449. https:\/\/doi.org\/10.3389\/fneur.2022.1041449.","journal-title":"Front Neurol"},{"key":"445_CR201","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1111\/joim.13541","volume":"292","author":"M Hariz","year":"2022","unstructured":"Hariz M, Blomstedt P. Deep brain stimulation for Parkinson\u2019s disease. J Intern Med. 2022;292:764\u201378. https:\/\/doi.org\/10.1111\/joim.13541.","journal-title":"J Intern Med"},{"key":"445_CR202","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1002\/mds.30179","volume":"40","author":"R Yan","year":"2025","unstructured":"Yan R, Zheng X, Yin Y, Zhang J, Cui Y, Su D, et al. Treatment for dyskinesia in Parkinson\u2019s disease: a network meta-analysis of randomized controlled trials. Mov Disord Off J Mov Disord Soc. 2025;40:869\u201380. https:\/\/doi.org\/10.1002\/mds.30179.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"445_CR203","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.3233\/JPD-202246","volume":"10","author":"SY Chiu","year":"2020","unstructured":"Chiu SY, Tsuboi T, Hegland KW, Herndon NE, Shukla AW, Patterson A, et al. Dysarthria and speech intelligibility following Parkinson\u2019s disease globus pallidus internus deep brain stimulation. J Park Dis. 2020;10:1493\u2013502. https:\/\/doi.org\/10.3233\/JPD-202246.","journal-title":"J Park Dis"},{"key":"445_CR204","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mds.29282","volume":"38","author":"S Pinto","year":"2023","unstructured":"Pinto S, Nebel A, Rau J, Espesser R, Maillochon P, Niebuhr O, et al. Results of a randomized clinical trial of speech after early neurostimulation in Parkinson\u2019s disease. Mov Disord Off J Mov Disord Soc. 2023;38:212\u201322. https:\/\/doi.org\/10.1002\/mds.29282.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"445_CR205","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1002\/mdc3.13206","volume":"8","author":"S Krishnan","year":"2021","unstructured":"Krishnan S, Shetty K, Puthanveedu DK, Kesavapisharady K, Thulaseedharan JV, Sarma G, et al. Apraxia of lid opening in subthalamic nucleus deep brain stimulation for Parkinson\u2019s disease-frequency, risk factors and response to treatment. Mov Disord Clin Pract. 2021;8:587\u201393. https:\/\/doi.org\/10.1002\/mdc3.13206.","journal-title":"Mov Disord Clin Pract"},{"key":"445_CR206","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/mds.28390","volume":"36","author":"TJC Zoon","year":"2021","unstructured":"Zoon TJC, van Rooijen G, Balm GMFC, Bergfeld IO, Daams JG, Krack P, et al. Apathy induced by subthalamic nucleus deep brain stimulation in Parkinson\u2019s disease: a meta-analysis. Mov Disord Off J Mov Disord Soc. 2021;36:317\u201326. https:\/\/doi.org\/10.1002\/mds.28390.","journal-title":"Mov Disord Off J Mov Disord Soc"},{"key":"445_CR207","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1056\/NEJMoa2202867","volume":"387","author":"G Pagano","year":"2022","unstructured":"Pagano G, Taylor KI, Anzures-Cabrera J, Marchesi M, Simuni T, Marek K, et al. Trial of prasinezumab in early-stage Parkinson\u2019s disease. N Engl J Med. 2022;387:421\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2202867.","journal-title":"N Engl J Med"},{"key":"445_CR208","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1038\/s41591-024-02886-y","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Taylor KI, Anzures Cabrera J, Simuni T, Marek K, Postuma RB, et al. Prasinezumab slows motor progression in rapidly progressing early-stage Parkinson\u2019s disease. Nat Med. 2024;30:1096\u2013103. https:\/\/doi.org\/10.1038\/s41591-024-02886-y.","journal-title":"Nat Med"},{"key":"445_CR209","doi-asserted-by":"publisher","first-page":"3669","DOI":"10.1038\/s41591-024-03270-6","volume":"30","author":"G Pagano","year":"2024","unstructured":"Pagano G, Monnet A, Reyes A, Ribba B, Svoboda H, Kustermann T, et al. Sustained effect of prasinezumab on Parkinson\u2019s disease motor progression in the open-label extension of the PASADENA trial. Nat Med. 2024;30:3669\u201375. https:\/\/doi.org\/10.1038\/s41591-024-03270-6.","journal-title":"Nat Med"},{"key":"445_CR210","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1038\/s41531-025-00886-4","volume":"11","author":"B Xiao","year":"2025","unstructured":"Xiao B, Tan E-K. Prasinezumab slows motor progression in Parkinsons disease: beyond the clinical data. NPJ Park Dis. 2025;11:31. https:\/\/doi.org\/10.1038\/s41531-025-00886-4.","journal-title":"NPJ Park Dis"},{"key":"445_CR211","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1038\/nature23664","volume":"548","author":"T Kikuchi","year":"2017","unstructured":"Kikuchi T, Morizane A, Doi D, Magotani H, Onoe H, Hayashi T, et al. Human iPS cell-derived dopaminergic neurons function in a primate Parkinson\u2019s disease model. Nature. 2017;548:592\u20136. https:\/\/doi.org\/10.1038\/nature23664.","journal-title":"Nature"},{"key":"445_CR212","doi-asserted-by":"publisher","first-page":"971","DOI":"10.1038\/s41586-025-08700-0","volume":"641","author":"N Sawamoto","year":"2025","unstructured":"Sawamoto N, Doi D, Nakanishi E, Sawamura M, Kikuchi T, Yamakado H, et al. Phase I\/II trial of iPS-cell-derived dopaminergic cells for Parkinson\u2019s disease. Nature. 2025;641:971\u20137. https:\/\/doi.org\/10.1038\/s41586-025-08700-0.","journal-title":"Nature"},{"key":"445_CR213","doi-asserted-by":"publisher","first-page":"606","DOI":"10.1038\/s41586-023-06300-4","volume":"619","author":"T-Y Park","year":"2023","unstructured":"Park T-Y, Jeon J, Lee N, Kim J, Song B, Kim J-H, et al. Co-transplantation of autologous Treg cells in a cell therapy for Parkinson\u2019s disease. Nature. 2023;619:606\u201315. https:\/\/doi.org\/10.1038\/s41586-023-06300-4.","journal-title":"Nature"},{"key":"445_CR214","doi-asserted-by":"publisher","first-page":"102114","DOI":"10.1016\/j.arr.2023.102114","volume":"92","author":"HM Mansour","year":"2023","unstructured":"Mansour HM, El-Khatib AS. Exploring Parkinson-associated kinases for CRISPR\/Cas9-based gene editing: beyond alpha-synuclein. Ageing Res Rev. 2023;92:102114. https:\/\/doi.org\/10.1016\/j.arr.2023.102114.","journal-title":"Ageing Res Rev"},{"key":"445_CR215","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1089\/crispr.2021.0025","volume":"5","author":"HH Yoon","year":"2022","unstructured":"Yoon HH, Ye S, Lim S, Jo A, Lee H, Hong F, et al. CRISPR-Cas9 gene editing protects from the A53T-SNCA overexpression-induced pathology of Parkinson\u2019s disease in vivo. CRISPR J. 2022;5:95\u2013108. https:\/\/doi.org\/10.1089\/crispr.2021.0025.","journal-title":"CRISPR J"},{"key":"445_CR216","doi-asserted-by":"publisher","first-page":"102044","DOI":"10.1016\/j.xcrm.2025.102044","volume":"6","author":"J Liu","year":"2025","unstructured":"Liu J, Zhu Y, Chen B, Meng Q, Hu P, Chen X, et al. Common and specific effects in brain oscillations and motor symptoms of tDCS and tACS in Parkinson\u2019s disease. Cell Rep Med. 2025;6:102044. https:\/\/doi.org\/10.1016\/j.xcrm.2025.102044.","journal-title":"Cell Rep Med"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00445-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-026-00445-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-026-00445-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T08:36:18Z","timestamp":1775637378000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-026-00445-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,8]]},"references-count":216,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["445"],"URL":"https:\/\/doi.org\/10.1186\/s43556-026-00445-0","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,8]]},"assertion":[{"value":"16 July 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 March 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"46"}}